Oncologic photodynamic therapy: Basic principles, current clinical status and future directions

Cancers

Volumn 9, Issue 2, 2017, Pages

  van Straten, Demian ^a   Mashayekhi, Vida ^a   de Bruijn, Henriette S ^b   Oliveira, Sabrina ^a   Robinson, Dominic J ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Clinical trials; Future; Photodynamic therapy; Preclinical; Treatment outcome

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; HYPERICIN; PADOPORFIN; PHOTOFRIN; PHOTOLON; PHOTOSENSITIZING AGENT; RADACHLORIN; TALAPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG; VERTEPORFIN;

ACTINIC KERATOSIS; AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; BILIARY TRACT CANCER; BRACHYTHERAPY; CHEMORADIOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FENTON REACTION; GLIOBLASTOMA; HUMAN; LIPOPHILICITY; META ANALYSIS (TOPIC); MOUTH SQUAMOUS CELL CARCINOMA; MULTICENTER STUDY (TOPIC); NON MUSCLE INVASIVE BLADDER CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHORESCENCE; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; TISSUE OXYGENATION; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU;

EID: 85013876030     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers9020019     Document Type: Review

References (386)

1. Dolmans, D.E.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3, 380–387. [CrossRef] [PubMed]
2. Bacellar, I.O.; Tsubone, T.M.; Pavani, C.; Baptista, M.S. Photodynamic efficiency: From molecular photochemistry to cell death. Int. J. Mol. Sci. 2015, 16, 20523–20559. [CrossRef] [PubMed]
3. Ackroyd, R.; Kelty, C.; Brown, N.; Reed, M. The history of photodetection and photodynamic therapy. Photochem. Photobiol. 2001, 74, 656–669. [CrossRef]
4. Celli, J.P.; Spring, B.Q.; Rizvi, I.; Evans, C.L.; Samkoe, K.S.; Verma, S.; Pogue, B.W.; Hasan, T. Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization. Chem. Rev. 2010, 110, 2795–2838. [CrossRef] [PubMed]
5. Raab, O. Uber die wirkung fluoreszierender stoffe auf infusorien. Zeitung Biol. 1900, 39, 524–526. (In German)
6. Prime, J. Des Accidents Toxiques Prodult par l’Eosinate se Sodium, 2nd ed.; Jouve et Boyer: Paris, France, 1900.
7. Von Tappeiner, H.A.; Jodlbauer, A. Die Sensibilisierende Wirkung Fluorescierender Substanzen: Gesammelte Untersuchungen über die Photodynamische Erscheinung; F.C.W. Vogel.: Leipzig, Germany, 1907. (In German)
8. Meyer-Betz, F. Untersuchungen uber die biologische photodynamische wirkung des hematoporphyrins und anderer derivative des blut und galenafarbstoffs. Dtsch. Arch. Klin. 1913, 112, 476–503. (In German)
9. Lipson, R.L.; Baldes, E.J.; Olsen, A.M. The use of a derivative of hematoporhyrin in tumor detection. J. Natl. Cancer Inst. 1961, 26, 1–11. [PubMed]
10. Diamond, I.; Granelli, S.G.; McDonagh, A.F.; Nielsen, S.; Wilson, C.B.; Jaenicke, R. Photodynamic therapy of malignant tumours. Lancet 1972, 2, 1175–1177. [CrossRef]
11. Dougherty, T.J.; Grindey, G.B.; Fiel, R.; Weishaupt, K.R.; Boyle, D.G. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J. Natl. Cancer Inst. 1975, 55, 115–121. [CrossRef] [PubMed]
12. Dougherty, T.J.; Kaufman, J.E.; Goldfarb, A.; Weishaupt, K.R.; Boyle, D.; Mittleman, A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978, 38, 2628–2635. [PubMed]
13. Henderson, B.W.; Dougherty, T.J. How does photodynamic therapy work? Photochem. Photobiol. 1992, 55, 145–157. [CrossRef] [PubMed]
14. Wagnieres, G.A.; Star, W.M.; Wilson, B.C. In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem. Photobiol. 1998, 68, 603–632. [CrossRef] [PubMed]
15. Foote, C.S. Definition of type I and type II photosensitized oxidation. Photochem. Photobiol. 1991, 54, 659. [CrossRef] [PubMed]
16. Plaetzer, K.; Krammer, B.; Berlanda, J.; Berr, F.; Kiesslich, T. Photophysics and photochemistry of photodynamic therapy: Fundamental aspects. Lasers Med. Sci. 2009, 24, 259–268. [CrossRef] [PubMed]
17. Sharman, W.M.; Allen, C.M.; van Lier, J.E. Role of activated oxygen species in photodynamic therapy. Methods Enzymol. 2000, 319, 376–400. [PubMed]
18. Moan, J.; Berg, K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem. Photobiol. 1991, 53, 549–553. [CrossRef] [PubMed]
19. Dysart, J.S.; Patterson, M.S. Characterization of photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of mll cells in vitro. Phys. Med. Biol. 2005, 50, 2597–2616. [CrossRef] [PubMed]
20. Oliveira, C.S.; Turchiello, R.; Kowaltowski, A.J.; Indig, G.L.; Baptista, M.S. Major determinants of photoinduced cell death: Subcellular localization versus photosensitization efficiency. Free Radic. Biol. Med. 2011, 51, 824–833. [CrossRef] [PubMed]
21. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part one-photosensitizers, photochemistry and cellular localization. Photodiagn. Photodyn. Ther. 2004, 1, 279–293. [CrossRef]
22. Juarranz, A.; Jaen, P.; Sanz-Rodriguez, F.; Cuevas, J.; Gonzalez, S. Photodynamic therapy of cancer. Basic principles and applications. Clin. Transl. Oncol. 2008, 10, 148–154. [CrossRef] [PubMed]
23. Igney, F.H.; Krammer, P.H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277–288. [CrossRef] [PubMed]
24. Oleinick, N.L.; Morris, R.L.; Belichenko, I. The role of apoptosis in response to photodynamic therapy: What, where, why, and how. Photochem. Photobiol. Sci 2002, 1, 1–21. [PubMed]
25. Kessel, D.; Reiners, J.J., Jr. Apoptosis and autophagy after mitochondrial or endoplasmic reticulum photodamage. Photochem. Photobiol. 2007, 83, 1024–1028. [CrossRef] [PubMed]
26. Wu, S.; Xing, D. Mechanism of mitochondrial membrane permeabilization during apoptosis under photofrin-mediated photodynamic therapy. J. Xray Sci. Technol. 2012, 20, 363–372. [PubMed]
27. Buytaert, E.; Dewaele, M.; Agostinis, P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim. Biophys. Acta 2007, 1776, 86–107. [CrossRef] [PubMed]
28. Mroz, P.; Yaroslavsky, A.; Kharkwal, G.B.; Hamblin, M.R. Cell death pathways in photodynamic therapy of cancer. Cancers 2011, 3, 2516–2539. [CrossRef] [PubMed]
29. Luo, Y.; Kessel, D. Initiation of apoptosis versus necrosis by photodynamic therapy with chloroaluminum phthalocyanine. Photochem. Photobiol. 1997, 66, 479–483. [CrossRef] [PubMed]
30. Lavie, G.; Kaplinsky, C.; Toren, A.; Aizman, I.; Meruelo, D.; Mazur, Y.; Mandel, M. A photodynamic pathway to apoptosis and necrosis induced by dimethyl tetrahydroxyhelianthrone and hypericin in leukaemic cells: Possible relevance to photodynamic therapy. Br. J. Cancer 1999, 79, 423–432. [CrossRef] [PubMed]
31. Nagata, S.; Obana, A.; Gohto, Y.; Nakajima, S. Necrotic and apoptotic cell death of human malignant melanoma cells following photodynamic therapy using an amphiphilic photosensitizer, ATX-S10(Na). Lasers Surg. Med. 2003, 33, 64–70. [CrossRef] [PubMed]
32. Hsieh, Y.J.; Wu, C.C.; Chang, C.J.; Yu, J.S. Subcellular localization of photofrin determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: When plasma membranes are the main targets. J. Cell. Physiol. 2003, 194, 363–375. [CrossRef] [PubMed]
33. Castano, A.P.; Mroz, P.; Hamblin, M.R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 2006, 6, 535–545. [CrossRef] [PubMed]
34. Levine, B.; Klionsky, D.J. Development by self-digestion: Molecular mechanisms and biological functions of autophagy. Dev. Cell 2004, 6, 463–477. [CrossRef]
35. Kessel, D.; Vicente, M.G.; Reiners, J.J., Jr. Initiation of apoptosis and autophagy by photodynamic therapy. Autophagy 2006, 2, 289–290. [CrossRef] [PubMed]
36. Buytaert, E.; Callewaert, G.; Hendrickx, N.; Scorrano, L.; Hartmann, D.; Missiaen, L.; Vandenheede, J.R.; Heirman, I.; Grooten, J.; Agostinis, P. Role of endoplasmic reticulum depletion and multidomain proapoptotic bax and bak proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J. 2006, 20, 756–758. [CrossRef] [PubMed]
37. Xue, L.Y.; Chiu, S.M.; Azizuddin, K.; Joseph, S.; Oleinick, N.L. The death of human cancer cells following photodynamic therapy: Apoptosis competence is necessary for Bcl-2 protection but not for induction of autophagy. Photochem. Photobiol. 2007, 83, 1016–1023. [CrossRef] [PubMed]
38. Kessel, D.; Oleinick, N.L. Initiation of autophagy by photodynamic therapy. Methods Enzymol. 2009, 453, 1–16. [PubMed]
39. Inguscio, V.; Panzarini, E.; Dini, L. Autophagy contributes to the death/survival balance in cancer photodynamic therapy. Cells 2012, 1, 464–491. [CrossRef] [PubMed]
40. Kessel, D.H.; Price, M.; Reiners, J.J., Jr. ATG7 deficiency suppresses apoptosis and cell death induced by lysosomal photodamage. Autophagy 2012, 8, 1333–1341. [CrossRef] [PubMed]
41. Hamblin, M.R.; Newman, E.L. On the mechanism of the tumour-localising effect in photodynamic therapy. J. Photochem. Photobiol. B 1994, 23, 3–8. [CrossRef]
42. Maeda, H.; Nakamura, H.; Fang, J. The epr effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65, 71–79. [CrossRef] [PubMed]
43. Boyle, R.W.; Dolphin, D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol. 1996, 64, 469–485. [CrossRef] [PubMed]
44. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part three-photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagn. Photodyn. Ther. 2005, 2, 91–106. [CrossRef]
45. Peng, Q.; Nesland, J.M. Effects of photodynamic therapy on tumor stroma. Ultrastruct. Pathol. 2004, 28, 333–340. [CrossRef] [PubMed]
46. Dvorak, H.F. Rous-whipple award lecture. How tumors make bad blood vessels and stroma. Am. J. Pathol. 2003, 162, 1747–1757. [CrossRef]
47. Hofmeister, V.; Schrama, D.; Becker, J.C. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother. 2008, 57, 1–17. [CrossRef] [PubMed]
48. Guo, W.; Giancotti, F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004, 5, 816–826. [CrossRef] [PubMed]
49. Desgrosellier, J.S.; Cheresh, D.A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10, 9–22. [CrossRef] [PubMed]
50. Celli, J.P. Stromal interactions as regulators of tumor growth and therapeutic response: A potential target for photodynamic therapy? Isr. J. Chem. 2012, 52, 757–766. [CrossRef] [PubMed]
51. Chen, B.; Pogue, B.W.; Zhou, X.; O’Hara, J.A.; Solban, N.; Demidenko, E.; Hoopes, P.J.; Hasan, T. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin. Cancer Res. 2005, 11, 720–727. [PubMed]
52. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [CrossRef]
53. Al-Husein, B.; Abdalla, M.; Trepte, M.; Deremer, D.L.; Somanath, P.R. Antiangiogenic therapy for cancer: An update. Pharmacotherapy 2012, 32, 1095–1111. [CrossRef] [PubMed]
54. Star, W.M.; Marijnissen, H.P.; van den Berg-Blok, A.E.; Versteeg, J.A.; Franken, K.A.; Reinhold, H.S. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 1986, 46, 2532–2540. [PubMed]
55. Fingar, V.H.; Kik, P.K.; Haydon, P.S.; Cerrito, P.B.; Tseng, M.; Abang, E.; Wieman, T.J. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer 1999, 79, 1702–1708. [CrossRef] [PubMed]
56. Ben-Hur, E.; Heldman, E.; Crane, S.W.; Rosenthal, I. Release of clotting factors from photosensitized endothelial cells: A possible trigger for blood vessel occlusion by photodynamic therapy. FEBS Lett. 1988, 236, 105–108. [CrossRef]
57. Foster, T.H.; Primavera, M.C.; Marder, V.J.; Hilf, R.; Sporn, L.A. Photosensitized release of von willebrand factor from cultured human endothelial cells. Cancer Res. 1991, 51, 3261–3266. [PubMed]
58. Nelson, J.S.; Liaw, L.H.; Berns, M.W. Tumor destruction in photodynamic therapy. Photochem. Photobiol. 1987, 46, 829–835. [CrossRef] [PubMed]
59. Fingar, V.H.; Wieman, T.J.; Haydon, P.S. The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochem. Photobiol. 1997, 66, 513–517. [CrossRef] [PubMed]
60. Kurohane, K.; Tominaga, A.; Sato, K.; North, J.R.; Namba, Y.; Oku, N. Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. 2001, 167, 49–56. [CrossRef]
61. Chen, B.; Pogue, B.W.; Hoopes, P.J.; Hasan, T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 1216–1226. [CrossRef] [PubMed]
62. Krzykawska-Serda, M.; Dabrowski, J.M.; Arnaut, L.G.; Szczygiel, M.; Urbanska, K.; Stochel, G.; Elas, M. The role of strong hypoxia in tumors after treatment in the outcome of bacteriochlorin-based photodynamic therapy. Free Radic. Biol. Med. 2014, 73, 239–251. [CrossRef] [PubMed]
63. Korbelik, M.; Sun, J.; Cecic, I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: Relevance for tumor response. Cancer Res. 2005, 65, 1018–1026. [PubMed]
64. Vabulas, R.M.; Wagner, H.; Schild, H. Heat shock proteins as ligands of toll-like receptors. Curr. Top. Microbiol. Immunol. 2002, 270, 169–184. [PubMed]
65. Beg, A.A. Endogenous ligands of toll-like receptors: Implications for regulating inflammatory and immune responses. Trends Immunol. 2002, 23, 509–512. [CrossRef]
66. Reginato, E.; Wolf, P.; Hamblin, M.R. Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects. World J. Immunol. 2014, 4, 1–11. [CrossRef] [PubMed]
67. Agarwal, M.L.; Larkin, H.E.; Zaidi, S.I.; Mukhtar, H.; Oleinick, N.L. Phospholipase activation triggers apoptosis in photosensitized mouse lymphoma cells. Cancer Res. 1993, 53, 5897–5902. [PubMed]
68. Garg, A.D.; Nowis, D.; Golab, J.; Agostinis, P. Photodynamic therapy: Illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010, 15, 1050–1071. [CrossRef] [PubMed]
69. Garg, A.D.; Nowis, D.; Golab, J.; Vandenabeele, P.; Krysko, D.V.; Agostinis, P. Immunogenic cell death, damps and anticancer therapeutics: An emerging amalgamation. Biochim. Biophys. Acta 2010, 1805, 53–71. [CrossRef] [PubMed]
70. Krosl, G.; Korbelik, M.; Dougherty, G.J. Induction of immune cell infiltration into murine sccvii tumour by photofrin-based photodynamic therapy. Br. J. Cancer 1995, 71, 549–555. [CrossRef] [PubMed]
71. Cecic, I.; Korbelik, M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett. 2002, 183, 43–51. [CrossRef]
72. Matroule, J.Y.; Volanti, C.; Piette, J. Nf-kappab in photodynamic therapy: Discrepancies of a master regulator. Photochem. Photobiol. 2006, 82, 1241–1246. [CrossRef] [PubMed]
73. Gollnick, S.O.; Evans, S.S.; Baumann, H.; Owczarczak, B.; Maier, P.; Vaughan, L.; Wang, W.C.; Unger, E.; Henderson, B.W. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br. J. Cancer 2003, 88, 1772–1779. [CrossRef] [PubMed]
74. De Vree, W.J.; Essers, M.C.; de Bruijn, H.S.; Star, W.M.; Koster, J.F.; Sluiter, W. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res. 1996, 56, 2908–2911. [PubMed]
75. Kousis, P.C.; Henderson, B.W.; Maier, P.G.; Gollnick, S.O. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 2007, 67, 10501–10510. [CrossRef] [PubMed]
76. Canti, G.; Lattuada, D.; Nicolin, A.; Taroni, P.; Valentini, G.; Cubeddu, R. Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light. Anticancer Drugs 1994, 5, 443–447. [CrossRef] [PubMed]
77. Korbelik, M.; Krosl, G.; Krosl, J.; Dougherty, G.J. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res. 1996, 56, 5647–5652. [PubMed]
78. Korbelik, M.; Dougherty, G.J. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 1999, 59, 1941–1946. [PubMed]
79. Larsson, M.; Fonteneau, J.F.; Bhardwaj, N. Dendritic cells resurrect antigens from dead cells. Trends Immunol. 2001, 22, 141–148. [CrossRef]
80. Hoffmann, T.K.; Meidenbauer, N.; Dworacki, G.; Kanaya, H.; Whiteside, T.L. Generation of tumor-specific t-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 2000, 60, 3542–3549. [PubMed]
81. + T cells and dependent on natural killer cells. Br. J. Cancer 2007, 96, 1839–1848. [CrossRef] [PubMed]
82. Gollnick, S.O.; Vaughan, L.; Henderson, B.W. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 2002, 62, 1604–1608. [PubMed]
83. Korbelik, M.; Sun, J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol. Immunother. 2006, 55, 900–909. [CrossRef] [PubMed]
84. Zhang, H.; Ma, W.; Li, Y. Generation of effective vaccines against liver cancer by using photodynamic therapy. Lasers Med. Sci. 2009, 24, 549–552. [CrossRef] [PubMed]
85. O’Connor, A.E.; Gallagher, W.M.; Byrne, A.T. Porphyrin and nonporphyrin photosensitizers in oncology: Preclinical and clinical advances in photodynamic therapy. Photochem. Photobiol. 2009, 85, 1053–1074. [CrossRef] [PubMed]
86. Ormond, A.B.; Freeman, H.S. Dye sensitizers for photodynamic therapy. Materials 2013, 6, 817–840. [CrossRef]
87. Yoon, I.; Li, J.Z.; Shim, Y.K. Advance in photosensitizers and light delivery for photodynamic therapy. Clin. Endosc. 2013, 46, 7–23. [CrossRef] [PubMed]
88. Szacilowski, K.; Macyk, W.; Drzewiecka-Matuszek, A.; Brindell, M.; Stochel, G. Bioinorganic photochemistry: Frontiers and mechanisms. Chem. Rev. 2005, 105, 2647–2694. [CrossRef] [PubMed]
89. Brancaleon, L.; Moseley, H. Laser and non-laser light sources for photodynamic therapy. Lasers Med. Sci. 2002, 17, 173–186. [CrossRef] [PubMed]
90. Pariser, D.; Loss, R.; Jarratt, M.; Abramovits, W.; Spencer, J.; Geronemus, R.; Bailin, P.; Bruce, S. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study. J. Am. Acad. Dermatol. 2008, 59, 569–576. [CrossRef] [PubMed]
91. Hino, H.; Murayama, Y.; Nakanishi, M.; Inoue, K.; Nakajima, M.; Otsuji, E. 5-aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes of different wavelengths in a mouse model of peritoneally disseminated gastric cancer. J. Surg. Res. 2013, 185, 119–126. [CrossRef] [PubMed]
92. Erkiert-Polguj, A.; Halbina, A.; Polak-Pacholczyk, I.; Rotsztejn, H. Light-emitting diodes in photodynamic therapy in non-melanoma skin cancers—Own observations and literature review. J. Cosmet. Laser Ther. 2016, 18, 105–110. [CrossRef] [PubMed]
93. Cantisani, C.; Paolino, G.; Bottoni, U.; Calvieri, S. Daylight-photodynamic therapy for the treatment of actinic keratosis in different seasons. J. Drugs Dermatol. 2015, 14, 1349–1353. [PubMed]
94. Lacour, J.P.; Ulrich, C.; Gilaberte, Y.; Von Felbert, V.; Basset-Seguin, N.; Dreno, B.; Girard, C.; Redondo, P.; Serra-Guillen, C.; Synnerstad, I.; et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: A randomised, investigator-blinded, controlled, phase iii study throughout europe. J. Eur. Acad. Dermatol. Venereol. 2015, 29, 2342–2348. [CrossRef] [PubMed]
95. Robinson, D.J.; de Bruijn, H.S.; van der Veen, N.; Stringer, M.R.; Brown, S.B.; Star, W.M. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: The effect of light dose and irradiance and the resulting biological effect. Photochem. Photobiol. 1998, 67, 140–149. [CrossRef] [PubMed]
96. Henderson, B.W.; Busch, T.M.; Snyder, J.W. Fluence rate as a modulator of PDT mechanisms. Lasers Surg. Med. 2006, 38, 489–493. [CrossRef] [PubMed]
97. De Bruijn, H.S.; Brooks, S.; van der Ploeg-van den Heuvel, A.; Ten Hagen, T.L.; de Haas, E.R.; Robinson, D.J. Light fractionation significantly increases the efficacy of photodynamic therapy using BF-200 ALA in normal mouse skin. PLoS ONE 2016, 11, e0148850. [CrossRef] [PubMed]
98. Henderson, B.W.; Gollnick, S.O.; Snyder, J.W.; Busch, T.M.; Kousis, P.C.; Cheney, R.T.; Morgan, J. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004, 64, 2120–2126. [CrossRef] [PubMed]
99. Sharikova, A.V.; Finlay, J.C.; Liang, X.; Zhu, T.C. PDT dose dosimetry for pleural photodynamic therapy. Proc. SPIE Int. Soc. Opt. Eng. 2013. [CrossRef]
100. Mordon, S.; Cochrane, C.; Tylcz, J.B.; Betrouni, N.; Mortier, L.; Koncar, V. Light emitting fabric technologies for photodynamic therapy. Photodiagn. Photodyn. Ther. 2015, 12, 1–8. [CrossRef] [PubMed]
101. Vignion-Dewalle, A.S.; Betrouni, N.; Tylcz, J.B.; Vermandel, M.; Mortier, L.; Mordon, S. Comparison of three light doses in the photodynamic treatment of actinic keratosis using mathematical modeling. J. Biomed. Opt. 2015. [CrossRef] [PubMed]
102. Guo, H.W.; Lin, L.T.; Chen, P.H.; Ho, M.H.; Huang, W.T.; Lee, Y.J.; Chiou, S.H.; Hsieh, Y.S.; Dong, C.Y.; Wang, H.W. Low-fluence rate, long duration photodynamic therapy in glioma mouse model using organic light emitting diode (OLED). Photodiagn. Photodyn. Ther. 2015, 12, 504–510. [CrossRef] [PubMed]
103. Vaupel, P.; Thews, O.; Hoeckel, M. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med. Oncol. 2001, 18, 243–259. [CrossRef]
104. Fuchs, J.; Thiele, J. The role of oxygen in cutaneous photodynamic therapy. Free Radic. Biol. Med. 1998, 24, 835–847. [CrossRef]
105. Lee See, K.; Forbes, I.J.; Betts, W.H. Oxygen dependency of photocytotoxicity with haematoporphyrin derivative. Photochem. Photobiol. 1984, 39, 631–634. [CrossRef] [PubMed]
106. Moan, J.; Sommer, S. Oxygen dependence of the photosensitizing effect of hematoporphyrin derivative in NHIK 3025 cells. Cancer Res. 1985, 45, 1608–1610. [PubMed]
107. Wyld, L.; Reed, M.W.; Brown, N.J. The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro. Br. J. Cancer 1998, 77, 1621–1627. [CrossRef] [PubMed]
108. Casas, A.; Di Venosa, G.; Hasan, T.; Al, B. Mechanisms of resistance to photodynamic therapy. Curr. Med. Chem. 2011, 18, 2486–2515. [CrossRef] [PubMed]
109. Fingar, V.H.; Wieman, T.J.; Park, Y.J.; Henderson, B.W. Implications of a pre-existing tumor hypoxic fraction on photodynamic therapy. J. Surg. Res. 1992, 53, 524–528. [CrossRef]
110. Al-Waili, N.S.; Butler, G.J.; Beale, J.; Hamilton, R.W.; Lee, B.Y.; Lucas, P. Hyperbaric oxygen and malignancies: A potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy. Med. Sci. Monit. 2005, 11, RA279–A289. [PubMed]
111. Chen, Q.; Huang, Z.; Chen, H.; Shapiro, H.; Beckers, J.; Hetzel, F.W. Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem. Photobiol. 2002, 76, 197–203. [CrossRef]
112. Huang, Z.; Chen, Q.; Shakil, A.; Chen, H.; Beckers, J.; Shapiro, H.; Hetzel, F.W. Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. Photochem. Photobiol. 2003, 78, 496–502. [CrossRef]
113. Delaey, E.; Vandenbogaerde, A.; Merlevede, W.; de Witte, P. Photocytotoxicity of hypericin in normoxic and hypoxic conditions. J. Photochem. Photobiol. B 2000, 56, 19–24. [CrossRef]
114. Price, M.; Heilbrun, L.; Kessel, D. Effects of the oxygenation level on formation of different reactive oxygen species during photodynamic therapy. Photochem. Photobiol. 2013, 89, 683–686. [CrossRef] [PubMed]
115. Chen, Q.; Chen, H.; Hetzel, F.W. Tumor oxygenation changes post-photodynamic therapy. Photochem. Photobiol. 1996, 63, 128–131. [CrossRef] [PubMed]
116. Benov, L. Photodynamic therapy: Current status and future directions. Med. Princ. Pract. 2015, 24 (Suppl. S1), 14–28. [CrossRef] [PubMed]
117. Akilov, O.E.; Kosaka, S.; O’Riordan, K.; Song, X.; Sherwood, M.; Flotte, T.J.; Foley, J.W.; Hasan, T. The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against leishmania parasites. Chem. Biol. 2006, 13, 839–847. [CrossRef] [PubMed]
118. Woodburn, K.W.; Vardaxis, N.J.; Hill, J.S.; Kaye, A.H.; Phillips, D.R. Subcellular localization of porphyrins using confocal laser scanning microscopy. Photochem. Photobiol. 1991, 54, 725–732. [CrossRef] [PubMed]
119. Dummin, H.; Cernay, T.; Zimmermann, H.W. Selective photosensitization of mitochondria in HeLa cells by cationic Zn (II) phthalocyanines with lipophilic side-chains. J. Photochem. Photobiol. B 1997, 37, 219–229. [CrossRef]
120. Jensen, T.J.; Vicente, M.G.; Luguya, R.; Norton, J.; Fronczek, F.R.; Smith, K.M. Effect of overall charge and charge distribution on cellular uptake, distribution and phototoxicity of cationic porphyrins in HEp2 cells. J. Photochem. Photobiol. B 2010, 100, 100–111. [CrossRef] [PubMed]
121. Ezzeddine, R.; Al-Banaw, A.; Tovmasyan, A.; Craik, J.D.; Batinic-Haberle, I.; Benov, L.T. Effect of molecular characteristics on cellular uptake, subcellular localization, and phototoxicity of Zn (II) N-alkylpyridylporphyrins. J. Biol. Chem. 2013, 288, 36579–36588. [CrossRef] [PubMed]
122. Pavani, C.; Uchoa, A.F.; Oliveira, C.S.; Iamamoto, Y.; Baptista, M.S. Effect of zinc insertion and hydrophobicity on the membrane interactions and PDT activity of porphyrin photosensitizers. Photochem. Photobiol. Sci. 2009, 8, 233–240. [CrossRef] [PubMed]
123. Zheng, G.; Potter, W.R.; Camacho, S.H.; Missert, J.R.; Wang, G.; Bellnier, D.A.; Henderson, B.W.; Rodgers, M.A.; Dougherty, T.J.; Pandey, R.K. Synthesis, photophysical properties, tumor uptake, and preliminary in vivo photosensitizing efficacy of a homologous series of 3-(1’-alkyloxy)ethyl-3-devinylpurpurin-18-n-alkylimides with variable lipophilicity. J. Med. Chem. 2001, 44, 1540–1559. [CrossRef] [PubMed]
124. Allison, R.R.; Sibata, C.H. Oncologic photodynamic therapy photosensitizers: A clinical review. Photodiagn. Photodyn. Ther. 2010, 7, 61–75. [CrossRef] [PubMed]
125. Rangasamy, S.; Ju, H.; Um, S.; Oh, D.C.; Song, J.M. Mitochondria and DNA targeting of 5,10,15,20-tetrakis(7-sulfonatobenzo[b]thiophene) porphyrin-induced photodynamic therapy via intrinsic and extrinsic apoptotic cell death. J. Med. Chem. 2015, 58, 6864–6874. [CrossRef] [PubMed]
126. Li, Y.; Wang, J.; Zhang, X.; Guo, W.; Li, F.; Yu, M.; Kong, X.; Wu, W.; Hong, Z. Highly water-soluble and tumor-targeted photosensitizers for photodynamic therapy. Org. Biomol. Chem. 2015, 13, 7681–7694. [CrossRef] [PubMed]
127. 2 -driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT. Oncogene 2016, 35, 3976–3985. [CrossRef] [PubMed]
128. Spano, V.; Parrino, B.; Carbone, A.; Montalbano, A.; Salvador, A.; Brun, P.; Vedaldi, D.; Diana, P.; Cirrincione, G.; Barraja, P. Pyrazolo[3,4-h]quinolines promising photosensitizing agents in the treatment of cancer. Eur J. Med. Chem. 2015, 102, 334–351. [PubMed]
129. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic therapy of cancer: An update. CA Cancer J. Clin. 2011, 61, 250–281. [CrossRef] [PubMed]
130. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int. J. Cancer 2015, 136, E359–E386. [CrossRef] [PubMed]
131. Scheff, R.J.; Schneider, B.J. Non-small-cell lung cancer: Treatment of late stage disease: Chemotherapeutics and new frontiers. Semin. Interv. Radiol. 2013, 30, 191–198. [CrossRef] [PubMed]
132. Weinberg, B.D.; Allison, R.R.; Sibata, C.; Parent, T.; Downie, G. Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer (NSCLC). Photodiagn. Photodyn. Ther. 2010, 7, 50–58. [CrossRef] [PubMed]
133. Ji, W.; Yoo, J.W.; Bae, E.K.; Lee, J.H.; Choi, C.M. The effect of Radachlorin® PDT in advanced NSCLC: A pilot study. Photodiagn. Photodyn. Ther. 2013, 10, 120–126. [CrossRef] [PubMed]
134. Ettinger, D.S.; Akerley, W.; Bepler, G.; Blum, M.G.; Chang, A.; Cheney, R.T.; Chirieac, L.R.; D’Amico, T.A.; Demmy, T.L.; Ganti, A.K.; et al. Non-small cell lung cancer. J. Natl. Compr. Cancer Netw. 2010, 8, 740–801.
135. Kimura, M.; Miyajima, K.; Kojika, M.; Kono, T.; Kato, H. Photodynamic therapy (PDT) with chemotherapy for advanced lung cancer with airway stenosis. Int. J. Mol. Sci. 2015, 16, 25466–25475. [CrossRef] [PubMed]
136. Akopov, A.; Rusanov, A.; Gerasin, A.; Kazakov, N.; Urtenova, M.; Chistyakov, I. Preoperative endobronchial photodynamic therapy improves resectability in initially irresectable (inoperable) locally advanced non small cell lung cancer. Photodiagn. Photodyn. Ther. 2014, 11, 259–264. [CrossRef] [PubMed]
137. Chen, K.C.; Hsieh, Y.S.; Tseng, Y.F.; Shieh, M.J.; Chen, J.S.; Lai, H.S.; Lee, J.M. Pleural photodynamic therapy and surgery in lung cancer and thymoma patients with pleural spread. PLoS ONE 2015, 10, e0133230. [CrossRef] [PubMed]
138. Friedberg, J.S.; Culligan, M.J.; Mick, R.; Stevenson, J.; Hahn, S.M.; Sterman, D.; Punekar, S.; Glatstein, E.; Cengel, K. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 2012, 93, 1658–1665; discussion 1665–1667. [CrossRef] [PubMed]
139. Cai, X.J.; Li, W.M.; Zhang, L.Y.; Wang, X.W.; Luo, R.C.; Li, L.B. Photodynamic therapy for intractable bronchial lung cancer. Photodiagn. Photodyn. Ther. 2013, 10, 672–676. [CrossRef] [PubMed]
140. Furukawa, K.; Kato, H.; Konaka, C.; Okunaka, T.; Usuda, J.; Ebihara, Y. Locally recurrent central-type early stage lung cancer <1.0 cm in diameter after complete remission by photodynamic therapy. Chest 2005, 128, 3269–3275. [PubMed]
141. Kato, H.; Usuda, J.; Okunaka, T.; Furukawa, K.; Honda, H.; Sakaniwa, N.; Suga, Y.; Hirata, T.; Ohtani, K.; Inoue, T.; et al. Basic and clinical research on photodynamic therapy at Tokyo Medical University Hospital. Lasers Surg. Med. 2006, 38, 371–375. [CrossRef] [PubMed]
142. Usuda, J.; Ichinose, S.; Ishizumi, T.; Hayashi, H.; Ohtani, K.; Maehara, S.; Ono, S.; Honda, H.; Kajiwara, N.; Uchida, O.; et al. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways >1.0 cm in diameter. Clin. Cancer Res. 2010, 16, 2198–2204. [CrossRef] [PubMed]
143. Usuda, J.; Ichinose, S.; Ishizumi, T.; Hayashi, H.; Ohtani, K.; Maehara, S.; Ono, S.; Kajiwara, N.; Uchida, O.; Tsutsui, H.; et al. Management of multiple primary lung cancer in patients with centrally located early cancer lesions. J. Thorac. Oncol. 2010, 5, 62–68. [CrossRef] [PubMed]
144. Bellnier, D.A.; Greco, W.R.; Loewen, G.M.; Nava, H.; Oseroff, A.R.; Pandey, R.K.; Tsuchida, T.; Dougherty, T.J. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 2003, 63, 1806–1813. [PubMed]
145. Dhillon, S.S.; Demmy, T.L.; Yendamuri, S.; Loewen, G.; Nwogu, C.; Cooper, M.; Henderson, B.W. A phase i study of light dose for photodynamic therapy using 2-[1-hexyloxyethyl]-2 devinyl pyropheophorbide-a for the treatment of non-small cell carcinoma in situ or non-small cell microinvasive bronchogenic carcinoma: A dose ranging study. J. Thorac. Oncol. 2016, 11, 234–241. [CrossRef] [PubMed]
146. Mazor, O.; Brandis, A.; Plaks, V.; Neumark, E.; Rosenbach-Belkin, V.; Salomon, Y.; Scherz, A. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem. Photobiol. 2005, 81, 342–351. [CrossRef] [PubMed]
147. Botterweck, A.A.; Schouten, L.J.; Volovics, A.; Dorant, E.; van Den Brandt, P.A. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten european countries. Int. J. Epidemiol. 2000, 29, 645–654. [CrossRef] [PubMed]
148. Cook, M.B.; Chow, W.H.; Devesa, S.S. Oesophageal cancer incidence in the united states by race, sex, and histologic type, 1977–2005. Br. J. Cancer 2009, 101, 855–859. [CrossRef] [PubMed]
149. Paul, S.; Altorki, N. Outcomes in the management of esophageal cancer. J. Surg. Oncol. 2014, 110, 599–610. [CrossRef] [PubMed]
150. Sjoquist, K.M.; Burmeister, B.H.; Smithers, B.M.; Zalcberg, J.R.; Simes, R.J.; Barbour, A.; Gebski, V.; Australasian Gastro-Intestinal Trials, G. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol. 2011, 12, 681–692. [CrossRef]
151. Ronellenfitsch, U.; Schwarzbach, M.; Hofheinz, R.; Kienle, P.; Kieser, M.; Slanger, T.E.; Jensen, K.; GE Adenocarcinoma meta analysis Group. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst. Rev. 2013. [CrossRef]
152. Keeley, S.B.; Pennathur, A.; Gooding, W.; Landreneau, R.J.; Christie, N.A.; Luketich, J. Photodynamic therapy with curative intent for barrett’s esophagus with high grade dysplasia and superficial esophageal cancer. Ann. Surg. Oncol. 2007, 14, 2406–2410. [CrossRef] [PubMed]
153. Yachimski, P.; Puricelli, W.P.; Nishioka, N.S. Patient predictors of histopathologic response after photodynamic therapy of barrett’s esophagus with high-grade dysplasia or intramucosal carcinoma. Gastrointest. Endosc. 2009, 69, 205–212. [CrossRef] [PubMed]
154. Gill, K.R.; Wolfsen, H.C.; Preyer, N.W.; Scott, M.V.; Gross, S.A.; Wallace, M.B.; Jones, L.R. Pilot study on light dosimetry variables for photodynamic therapy of barrett’s esophagus with high-grade dysplasia. Clin. Cancer Res. 2009, 15, 1830–1836. [CrossRef] [PubMed]
155. Prasad, G.A.; Wang, K.K.; Halling, K.C.; Buttar, N.S.; Wongkeesong, L.M.; Zinsmeister, A.R.; Brankley, S.M.; Fritcher, E.G.; Westra, W.M.; Krishnadath, K.K.; et al. Utility of biomarkers in prediction of response to ablative therapy in barrett’s esophagus. Gastroenterology 2008, 135, 370–379. [CrossRef] [PubMed]
156. Prasad, G.A.; Wang, K.K.; Halling, K.C.; Buttar, N.S.; Wongkeesong, L.M.; Zinsmeister, A.R.; Brankley, S.M.; Westra, W.M.; Lutzke, L.S.; Borkenhagen, L.S.; et al. Correlation of histology with biomarker status after photodynamic therapy in barrett esophagus. Cancer 2008, 113, 470–476. [CrossRef] [PubMed]
157. Yoon, H.Y.; Cheon, Y.K.; Choi, H.J.; Shim, C.S. Role of photodynamic therapy in the palliation of obstructing esophageal cancer. Korean J. Intern. Med. 2012, 27, 278–284. [CrossRef] [PubMed]
158. Yano, T.; Muto, M.; Minashi, K.; Ohtsu, A.; Yoshida, S. Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer. Gastrointest. Endosc. 2005, 62, 31–36. [CrossRef]
159. Yano, T.; Muto, M.; Hattori, S.; Minashi, K.; Onozawa, M.; Nihei, K.; Ishikura, S.; Ohtsu, A.; Yoshida, S. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 2008, 40, 717–721. [CrossRef] [PubMed]
160. Yano, T.; Hatogai, K.; Morimoto, H.; Yoda, Y.; Kaneko, K. Photodynamic therapy for esophageal cancer. Ann. Transl. Med. 2014. [CrossRef]
161. Prasad, G.A.; Wang, K.K.; Buttar, N.S.; Wongkeesong, L.M.; Krishnadath, K.K.; Nichols, F.C., III; Lutzke, L.S.; Borkenhagen, L.S. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in barrett’s esophagus. Gastroenterology 2007, 132, 1226–1233. [CrossRef] [PubMed]
162. Gray, J.; Fullarton, G.M. Long term efficacy of photodynamic therapy (PDT) as an ablative therapy of high grade dysplasia in barrett’s oesophagus. Photodiagn. Photodyn. Ther. 2013, 10, 561–565. [CrossRef] [PubMed]
163. David, W.J.; Qumseya, B.J.; Qumsiyeh, Y.; Heckman, M.G.; Diehl, N.N.; Wallace, M.B.; Raimondo, M.; Woodward, T.A.; Wolfsen, H.C. Comparison of endoscopic treatment modalities for barrett’s neoplasia. Gastrointest. Endosc. 2015, 82, 793–803. [CrossRef] [PubMed]
164. Mackenzie, G.D.; Dunn, J.M.; Selvasekar, C.R.; Mosse, C.A.; Thorpe, S.M.; Novelli, M.R.; Bown, S.G.; Lovat, L.B. Optimal conditions for successful ablation of high-grade dysplasia in barrett’s oesophagus using aminolaevulinic acid photodynamic therapy. Lasers Med. Sci. 2009, 24, 729–734. [CrossRef] [PubMed]
165. Dunn, J.M.; Mackenzie, G.D.; Banks, M.R.; Mosse, C.A.; Haidry, R.; Green, S.; Thorpe, S.; Rodriguez-Justo, M.; Winstanley, A.; Novelli, M.R.; et al. A randomised controlled trial of ALA vs. Photofrin photodynamic therapy for high-grade dysplasia arising in barrett’s oesophagus. Lasers Med. Sci. 2013, 28, 707–715. [CrossRef] [PubMed]
166. Nava, H.R.; Allamaneni, S.S.; Dougherty, T.J.; Cooper, M.T.; Tan, W.; Wilding, G.; Henderson, B.W. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with barrett’s esophagus. Lasers Surg. Med. 2011, 43, 705–712. [CrossRef] [PubMed]
167. Yano, T.; Muto, M.; Yoshimura, K.; Niimi, M.; Ezoe, Y.; Yoda, Y.; Yamamoto, Y.; Nishisaki, H.; Higashino, K.; Iishi, H. Phase I study of photodynamic therapy using talaporfin sodium and diode laser for local failure after chemoradiotherapy for esophageal cancer. Radiat. Oncol. 2012. [CrossRef] [PubMed]
168. Yano, T.; Muto, M.; Minashi, K.; Iwasaki, J.; Kojima, T.; Fuse, N.; Doi, T.; Kaneko, K.; Ohtsu, A. Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: A phase II study. Int. J. Cancer 2012, 131, 1228–1234. [CrossRef] [PubMed]
169. Gallagher, R.P.; Lee, T.K.; Bajdik, C.D.; Borugian, M. Ultraviolet radiation. Chronic Dis. Can. 2010, 29 (Suppl. S1), 51–68. [PubMed]
170. Stewart, B.W.; Wild, C.P. World Cancer Report 2014; IARC Publications: Lyon, France, 2014; p. 630.
171. Zeitouni, N.C.; Oseroff, A.R.; Shieh, S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol. Immunol. 2003, 39, 1133–1136. [CrossRef]
172. Kennedy, J.C.; Pottier, R.H.; Pross, D.C. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J. Photochem. Photobiol. B 1990, 6, 143–148. [CrossRef]
173. Gerritsen, M.J.; Smits, T.; Kleinpenning, M.M.; van de Kerkhof, P.C.; van Erp, P.E. Pretreatment to enhance protoporphyrin IX accumulation in photodynamic therapy. Dermatology 2009, 218, 193–202. [CrossRef] [PubMed]
174. Maisch, T.; Santarelli, F.; Schreml, S.; Babilas, P.; Szeimies, R.M. Fluorescence induction of protoporphyrin IX by a new 5-aminolevulinic acid nanoemulsion used for photodynamic therapy in a full-thickness ex vivo skin model. Exp. Dermatol. 2010, 19, e302–e305. [CrossRef] [PubMed]
175. De Bruijn, H.S.; van der Veen, N.; Robinson, D.J.; Star, W.M. Improvement of systemic 5-aminolevulinic acid-based photodynamic therapy in vivo using light fractionation with a 75-minute interval. Cancer Res. 1999, 59, 901–904. [PubMed]
176. Kuijpers, D.I.; Thissen, M.R.; Thissen, C.A.; Neumann, M.H. Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma. J. Drugs Dermatol. 2006, 5, 642–645. [PubMed]
177. Tarstedt, M.; Gillstedt, M.; Wennberg Larko, A.M.; Paoli, J. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 420–423. [CrossRef] [PubMed]
178. Szeimies, R.M.; Ibbotson, S.; Murrell, D.F.; Rubel, D.; Frambach, Y.; de Berker, D.; Dummer, R.; Kerrouche, N.; Villemagne, H.; Excilight Study, G. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8–20 mm), with a 12-month follow-up. J. Eur. Acad. Dermatol. Venereol. 2008, 22, 1302–1311. [CrossRef] [PubMed]
179. Arits, A.H.; Mosterd, K.; Essers, B.A.; Spoorenberg, E.; Sommer, A.; De Rooij, M.J.; van Pelt, H.P.; Quaedvlieg, P.J.; Krekels, G.A.; van Neer, P.A.; et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: A single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013, 14, 647–654. [CrossRef]
180. De Vijlder, H.C.; Sterenborg, H.J.; Neumann, H.A.; Robinson, D.J.; de Haas, E.R. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: Five-year follow-up of a randomized, prospective trial. Acta Derm. Venereol. 2012, 92, 641–647. [CrossRef] [PubMed]
181. Cottrell, W.J.; Paquette, A.D.; Keymel, K.R.; Foster, T.H.; Oseroff, A.R. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. Clin. Cancer Res. 2008, 14, 4475–4483. [CrossRef] [PubMed]
182. Zeitouni, N.C.; Sunar, U.; Rohrbach, D.J.; Paquette, A.D.; Bellnier, D.A.; Shi, Y.; Wilding, G.; Foster, T.H.; Henderson, B.W. A prospective study of pain control by a 2-step irradiance schedule during topical photodynamic therapy of nonmelanoma skin cancer. Dermatol. Surg. 2014, 40, 1390–1394. [CrossRef] [PubMed]
183. Moloney, F.J.; Collins, P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br. J. Dermatol. 2007, 157, 87–91. [CrossRef] [PubMed]
184. Kasche, A.; Luderschmidt, S.; Ring, J.; Hein, R. Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J. Drugs Dermatol. 2006, 5, 353–356. [PubMed]
185. Dirschka, T.; Radny, P.; Dominicus, R.; Mensing, H.; Bruning, H.; Jenne, L.; Karl, L.; Sebastian, M.; Oster-Schmidt, C.; Klovekorn, W.; et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: Results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br. J. Dermatol. 2012, 166, 137–146. [CrossRef] [PubMed]
186. Dirschka, T.; Radny, P.; Dominicus, R.; Mensing, H.; Bruning, H.; Jenne, L.; Karl, L.; Sebastian, M.; Oster-Schmidt, C.; Klovekorn, W.; et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br. J. Dermatol. 2013, 168, 825–836. [CrossRef] [PubMed]
187. Gholam, P.; Weberschock, T.; Denk, K.; Enk, A. Treatment with 5-aminolaevulinic acid methylester is less painful than treatment with 5-aminolaevulinic acid nanoemulsion in topical photodynamic therapy for actinic keratosis. Dermatology 2011, 222, 358–362. [CrossRef] [PubMed]
188. Neittaanmaki-Perttu, N.; Karppinen, T.T.; Gronroos, M.; Tani, T.T.; Snellman, E. Daylight photodynamic therapy for actinic keratoses: A randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate. Br. J. Dermatol. 2014, 171, 1172–1180. [CrossRef] [PubMed]
189. Argiris, A.; Karamouzis, M.V.; Raben, D.; Ferris, R.L. Head and neck cancer. Lancet 2008, 371, 1695–1709. [CrossRef]
190. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [CrossRef] [PubMed]
191. Marchal, S.; Dolivet, G.; Lassalle, H.P.; Guillemin, F.; Bezdetnaya, L. Targeted photodynamic therapy in head and neck squamous cell carcinoma: Heading into the future. Lasers Med. Sci. 2015, 30, 2381–2387. [CrossRef] [PubMed]
192. Feyh, J.; Goetz, A.; Muller, W.; Konigsberger, R.; Kastenbauer, E. Photodynamic therapy in head and neck surgery. J. Photochem. Photobiol. B 1990, 7, 353–358. [CrossRef]
193. Feyh, J. Photodynamic treatment for cancers of the head and neck. J. Photochem. Photobiol. B 1996, 36, 175–177. [CrossRef]
194. Ikeda, H.; Tobita, T.; Ohba, S.; Uehara, M.; Asahina, I. Treatment outcome of photofrin-based photodynamic therapy for T1 and T2 oral squamous cell carcinoma and dysplasia. Photodiagn. Photodyn. Ther. 2013, 10, 229–235. [CrossRef] [PubMed]
195. Dilkes, M.G.; DeJode, M.L.; Gardiner, Q.; Kenyon, G.S.; McKelvie, P. Treatment of head and neck cancer with photodynamic therapy: Results after one year. J. Laryngol. Otol. 1995, 109, 1072–1076. [CrossRef] [PubMed]
196. Copper, M.P.; Tan, I.B.; Oppelaar, H.; Ruevekamp, M.C.; Stewart, F.A. Meta-tetra(hydroxyphenyl)chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2003, 129, 709–711. [CrossRef] [PubMed]
197. Rigual, N.; Shafirstein, G.; Cooper, M.T.; Baumann, H.; Bellnier, D.A.; Sunar, U.; Tracy, E.C.; Rohrbach, D.J.; Wilding, G.; Tan, W.; et al. Photodynamic therapy with 3-(1’-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity. Clin. Cancer Res. 2013, 19, 6605–6613. [CrossRef] [PubMed]
198. Shafirstein, G.; Rigual, N.R.; Arshad, H.; Cooper, M.T.; Bellnier, D.A.; Wilding, G.; Tan, W.; Merzianu, M.; Henderson, B.W. Photodynamic therapy with 3-(1’-hexyloxyethyl) pyropheophorbide-a for early-stage cancer of the larynx: Phase ib study. Head Neck 2016, 38 (Suppl. S1), E377–E383. [CrossRef] [PubMed]
199. Hopper, C. Photodynamic therapy: A clinical reality in the treatment of cancer. Lancet Oncol. 2000, 1, 212–219. [CrossRef]
200. Lou, P.J.; Jager, H.R.; Jones, L.; Theodossy, T.; Bown, S.G.; Hopper, C. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br. J. Cancer 2004, 91, 441–446. [CrossRef] [PubMed]
201. Jerjes, W.; Upile, T.; Hamdoon, Z.; Mosse, C.A.; Akram, S.; Hopper, C. Photodynamic therapy outcome for oral dysplasia. Lasers Surg. Med. 2011, 43, 192–199. [CrossRef] [PubMed]
202. Jerjes, W.; Upile, T.; Hamdoon, Z.; Alexander Mosse, C.; Morcos, M.; Hopper, C. Photodynamic therapy outcome for T1/T2 N0 oral squamous cell carcinoma. Lasers Surg. Med. 2011, 43, 463–469. [CrossRef] [PubMed]
203. Shikowitz, M.J.; Abramson, A.L.; Steinberg, B.M.; DeVoti, J.; Bonagura, V.R.; Mullooly, V.; Nouri, M.; Ronn, A.M.; Inglis, A.; McClay, J.; et al. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 2005, 131, 99–105. [CrossRef] [PubMed]
204. Kubler, A.C.; de Carpentier, J.; Hopper, C.; Leonard, A.G.; Putnam, G. Treatment of squamous cell carcinoma of the lip using foscan-mediated photodynamic therapy. Int. J. Oral Maxillofac. Surg. 2001, 30, 504–509. [CrossRef] [PubMed]
205. Fan, K.F.; Hopper, C.; Speight, P.M.; Buonaccorsi, G.A.; Bown, S.G. Photodynamic therapy using mTHPC for malignant disease in the oral cavity. Int. J. Cancer 1997, 73, 25–32. [CrossRef]
206. Karakullukcu, B.; Stoker, S.D.; Wildeman, A.P.; Copper, M.P.; Wildeman, M.A.; Tan, I.B. A matched cohort comparison of mthpc-mediated photodynamic therapy and trans-oral surgery of early stage oral cavity squamous cell cancer. Eur. Arch. Otorhinolaryngol. 2013, 270, 1093–1097. [CrossRef] [PubMed]
207. De Visscher, S.A.; Melchers, L.J.; Dijkstra, P.U.; Karakullukcu, B.; Tan, I.B.; Hopper, C.; Roodenburg, J.L.; Witjes, M.J. mTHPC-mediated photodynamic therapy of early stage oral squamous cell carcinoma: A comparison to surgical treatment. Ann. Surg. Oncol. 2013, 20, 3076–3082. [CrossRef] [PubMed]
208. Stoker, S.D.; Indrasari, S.R.; Herdini, C.; Hariwiyanto, B.; Karakullukcu, B.; Dhamiyati, W.; Widayati, K.; Romdhoni, A.C.; Fles, R.; Haryana, S.M.; et al. Photodynamic therapy as salvage therapy for patients with nasopharyngeal carcinoma experiencing local failures following definitive radiotherapy. Photodiagn. Photodyn. Ther. 2015, 12, 519–525. [CrossRef] [PubMed]
209. Jerjes, W.; Upile, T.; Hamdoon, Z.; Nhembe, F.; Bhandari, R.; Mackay, S.; Shah, P.; Mosse, C.A.; Brookes, J.A.; Morley, S.; et al. Ultrasound-guided photodynamic therapy for deep seated pathologies: Prospective study. Lasers Surg. Med. 2009, 41, 612–621. [CrossRef] [PubMed]
210. Tan, I.B.; Dolivet, G.; Ceruse, P.; Vander Poorten, V.; Roest, G.; Rauschning, W. Temoporfin-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: A multicenter study. Head Neck 2010, 32, 1597–1604. [CrossRef] [PubMed]
211. Vander Poorten, V.; Meulemans, J.; Nuyts, S.; Clement, P.; Hermans, R.; Hauben, E.; Delaere, P. Postoperative photodynamic therapy as a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell carcinoma of the base of tongue. World J. Surg. Oncol. 2015. [CrossRef] [PubMed]
212. Caesar, L.; Lorenz, K.J.; Tan, B.; Karakullukcu, B.; Aans, J.B.; Dilici, A. Photodynamic therapy in the treatment of recurrent sino-nasal skull base tumors. In Proceedings of the 85th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery, Dortmund, Germany, 28 May–1 June 2014; GMS Publishing House: Dortmund, Germany, 2014.
213. Caesar, L.; van Doeveren, T.E.; Tan, I.B.; Dilci, A.; van Veen, R.L.; Karakullukcu, B. The use of photodynamic therapy as adjuvant therapy to surgery in recurrent malignant tumors of the paranasal sinuses. Photodiagn. Photodyn. Ther. 2015, 12, 414–421. [CrossRef] [PubMed]
214. Esnaola, N.F.; Meyer, J.E.; Karachristos, A.; Maranki, J.L.; Camp, E.R.; Denlinger, C.S. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer 2016, 122, 1349–1369. [CrossRef] [PubMed]
215. Patel, T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the united states. Hepatology 2001, 33, 1353–1357. [CrossRef] [PubMed]
216. McCaughan, J.S., Jr.; Mertens, B.F.; Cho, C.; Barabash, R.D.; Payton, H.W. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch. Surg. 1991, 126, 111–113. [CrossRef] [PubMed]
217. Leggett, C.L.; Gorospe, E.C.; Murad, M.H.; Montori, V.M.; Baron, T.H.; Wang, K.K. Photodynamic therapy for unresectable cholangiocarcinoma: A comparative effectiveness systematic review and meta-analyses. Photodiagn. Photodyn. Ther. 2012, 9, 189–195. [CrossRef] [PubMed]
218. Nanashima, A.; Abo, T.; Nonaka, T.; Nonaka, Y.; Morisaki, T.; Uehara, R.; Ohnita, K.; Fukuda, D.; Murakami, G.; Tou, K.; et al. Photodynamic therapy using talaporfin sodium (laserphyrin(r)) for bile duct carcinoma: A preliminary clinical trial. AntiCancer Res. 2012, 32, 4931–4938. [CrossRef] [PubMed]
219. Berr, F.; Tannapfel, A.; Lamesch, P.; Pahernik, S.; Wiedmann, M.; Halm, U.; Goetz, A.E.; Mossner, J.; Hauss, J. Neoadjuvant photodynamic therapy before curative resection of proximal bile duct carcinoma. J. Hepatol. 2000, 32, 352–357. [CrossRef]
220. Wagner, A.; Kiesslich, T.; Neureiter, D.; Friesenbichler, P.; Puespoek, A.; Denzer, U.W.; Wolkersdorfer, G.W.; Emmanuel, K.; Lohse, A.W.; Berr, F. Photodynamic therapy for hilar bile duct cancer: Clinical evidence for improved tumoricidal tissue penetration by temoporfin. Photochem. Photobiol. Sci 2013, 12, 1065–1073. [CrossRef] [PubMed]
221. Wagner, A.; Denzer, U.W.; Neureiter, D.; Kiesslich, T.; Puespoeck, A.; Rauws, E.A.; Emmanuel, K.; Degenhardt, N.; Frick, U.; Beuers, U.; et al. Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase ii study. Hepatology 2015, 62, 1456–1465. [CrossRef] [PubMed]
222. Kniebuhler, G.; Pongratz, T.; Betz, C.S.; Goke, B.; Sroka, R.; Stepp, H.; Schirra, J. Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan®). Photodiagn. Photodyn. Ther. 2013, 10, 220–228. [CrossRef] [PubMed]
223. Park, D.H.; Lee, S.S.; Park, S.E.; Lee, J.L.; Choi, J.H.; Choi, H.J.; Jang, J.W.; Kim, H.J.; Eum, J.B.; Seo, D.W.; et al. Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma. Eur. J. Cancer 2014, 50, 1259–1268. [CrossRef] [PubMed]
224. Wentrup, R.; Winkelmann, N.; Mitroshkin, A.; Prager, M.; Voderholzer, W.; Schachschal, G.; Jurgensen, C.; Buning, C. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma. Gut Liver 2016, 10, 470–475. [CrossRef] [PubMed]
225. Nanashima, A.; Isomoto, H.; Abo, T.; Nonaka, T.; Morisaki, T.; Arai, J.; Takagi, K.; Ohnita, K.; Shoji, H.; Urabe, S.; et al. How to access photodynamic therapy for bile duct carcinoma. Ann. Transl. Med. 2014. [CrossRef]
226. Choi, J.H.; Oh, D.; Lee, J.H.; Park, J.H.; Kim, K.P.; Lee, S.S.; Lee, Y.J.; Lim, Y.S.; Song, T.J.; Lee, S.S.; et al. Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter. Endoscopy 2015, 47, 1035–1038. [CrossRef] [PubMed]
227. Burkhart, R.A.; Laheru, D.A.; Herman, J.M.; Pawlik, T.M. Multidisciplinary management and the future of treatment in cholangiocarcinoma. Expert Opin. Orphan Drugs 2016, 4, 255–267. [CrossRef]
228. Falasca, M.; Kim, M.; Casari, I. Pancreatic cancer: Current research and future directions. Biochim. Biophys. Acta 2016, 1865, 123–132. [CrossRef] [PubMed]
229. Bramhall, S.R.; Allum, W.H.; Jones, A.G.; Allwood, A.; Cummins, C.; Neoptolemos, J.P. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the west midlands: An epidemiological study. Br. J. Surg. 1995, 82, 111–115. [CrossRef] [PubMed]
230. Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369, 1691–1703. [CrossRef] [PubMed]
231. Bown, S.G.; Rogowska, A.Z.; Whitelaw, D.E.; Lees, W.R.; Lovat, L.B.; Ripley, P.; Jones, L.; Wyld, P.; Gillams, A.; Hatfield, A.W. Photodynamic therapy for cancer of the pancreas. Gut 2002, 50, 549–557. [CrossRef] [PubMed]
232. Huggett, M.T.; Jermyn, M.; Gillams, A.; Illing, R.; Mosse, S.; Novelli, M.; Kent, E.; Bown, S.G.; Hasan, T.; Pogue, B.W.; et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br. J. Cancer 2014, 110, 1698–1704. [CrossRef] [PubMed]
233. Sylvester, R.J.; van der Meijden, A.P.; Oosterlinck, W.; Witjes, J.A.; Bouffioux, C.; Denis, L.; Newling, D.W.; Kurth, K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using eortc risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006, 49, 466–477. [CrossRef] [PubMed]
234. Lee, J.Y.; Diaz, R.R.; Cho, K.S.; Lim, M.S.; Chung, J.S.; Kim, W.T.; Ham, W.S.; Choi, Y.D. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille calmette-guerin immunotherapy. J. Urol. 2013, 190, 1192–1199. [CrossRef] [PubMed]
235. Bader, M.J.; Stepp, H.; Beyer, W.; Pongratz, T.; Sroka, R.; Kriegmair, M.; Zaak, D.; Welschof, M.; Tilki, D.; Stief, C.G.; et al. Photodynamic therapy of bladder cancer—A phase I study using hexaminolevulinate (HAL). Urol. Oncol. 2013, 31, 1178–1183. [CrossRef] [PubMed]
236. Hillemanns, P.; Einstein, M.H.; Iversen, O.E. Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia. Expert Opin. Investig. Drugs 2015, 24, 273–281. [CrossRef] [PubMed]
237. Hahn, S.M.; Fraker, D.L.; Mick, R.; Metz, J.; Busch, T.M.; Smith, D.; Zhu, T.; Rodriguez, C.; Dimofte, A.; Spitz, F.; et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin. Cancer Res. 2006, 12, 2517–2525. [CrossRef] [PubMed]
238. Wang, J.; Xu, J.; Chen, J.; He, Q.; Xiang, L.; Huang, X.; Ding, G.; Xu, S. Successful photodynamic therapy with topical 5-aminolevulinic acid for five cases of cervical intraepithelial neoplasia. Arch. Gynecol. Obstet. 2010, 282, 307–312. [CrossRef] [PubMed]
239. Istomin, Y.P.; Lapzevich, T.P.; Chalau, V.N.; Shliakhtsin, S.V.; Trukhachova, T.V. Photodynamic therapy of cervical intraepithelial neoplasia grades ii and iii with photolon. Photodiagn. Photodyn. Ther. 2010, 7, 144–151. [CrossRef] [PubMed]
240. 2 laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol. Oncol. 2006, 100, 271–275. [CrossRef] [PubMed]
241. Choi, M.C.; Kim, M.S.; Lee, G.H.; Jung, S.G.; Park, H.; Joo, W.D.; Lee, C.; Lee, J.H.; Hwang, Y.Y.; Kim, S.J. Photodynamic therapy for premalignant lesions of the vulva and vagina: A long-term follow-up study. Lasers Surg. Med. 2015, 47, 566–570. [CrossRef] [PubMed]
242. Hillemanns, P.; Wang, X.; Hertel, H.; Andikyan, V.; Hillemanns, M.; Stepp, H.; Soergel, P. Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. Am. J. Obstet. Gynecol. 2008, 198, 300.e1–300.e7. [CrossRef] [PubMed]
243. Soergel, P.; Wang, X.; Stepp, H.; Hertel, H.; Hillemanns, P. Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate. Lasers Surg. Med. 2008, 40, 611–615. [CrossRef] [PubMed]
244. Soergel, P.; Dahl, G.F.; Onsrud, M.; Hillemanns, P. Photodynamic therapy of cervical intraepithelial neoplasia 1–3 and human papilloma virus (HMV) infection with methylaminolevulinate and hexaminolevulinate—A double-blind, dose-finding study. Lasers Surg. Med. 2012, 44, 468–474. [CrossRef] [PubMed]
245. Hillemanns, P.; Petry, K.U.; Soergel, P.; Collinet, P.; Ardaens, K.; Gallwas, J.; Luyten, A.; Dannecker, C. Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia. Lasers Surg. Med. 2014, 46, 456–461. [CrossRef] [PubMed]
246. Hillemanns, P.; Garcia, F.; Petry, K.U.; Dvorak, V.; Sadovsky, O.; Iversen, O.E.; Einstein, M.H. A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. Am. J. Obstet. Gynecol. 2015, 212, 465.e1–465.e7. [CrossRef] [PubMed]
247. Soergel, P.; Loehr-Schulz, R.; Hillemanns, M.; Landwehr, S.; Makowski, L.; Hillemanns, P. Effects of photodynamic therapy using topical applied hexylaminolevulinate and methylaminolevulinate upon the integrity of cervical epithelium. Lasers Surg. Med. 2010, 42, 624–630. [CrossRef] [PubMed]
248. Wilt, T.J.; MacDonald, R.; Rutks, I.; Shamliyan, T.A.; Taylor, B.C.; Kane, R.L. Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann. Intern. Med. 2008, 148, 435–448. [CrossRef] [PubMed]
249. Sultan, S.M.; El-Doray, A.A.; Hofstetter, A.; Abdel-Gawad, O.; El-Mahdy Ael, D.; Khoder, W. Photodynamic selectivity of 5-aminolevulinic acid to prostate cancer cells. J. Egypt. Natl. Cancer Inst. 2006, 18, 382–386.
250. Moore, C.M.; Nathan, T.R.; Lees, W.R.; Mosse, C.A.; Freeman, A.; Emberton, M.; Bown, S.G. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Lasers Surg. Med. 2006, 38, 356–363. [CrossRef] [PubMed]
251. Trachtenberg, J.; Bogaards, A.; Weersink, R.A.; Haider, M.A.; Evans, A.; McCluskey, S.A.; Scherz, A.; Gertner, M.R.; Yue, C.; Appu, S.; et al. Vascular targeted photodynamic therapy with palladiumbacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: Assessment of safety and treatment response. J. Urol. 2007, 178, 1974–1979; discussion 1979. [CrossRef] [PubMed]
252. Trachtenberg, J.; Weersink, R.A.; Davidson, S.R.; Haider, M.A.; Bogaards, A.; Gertner, M.R.; Evans, A.; Scherz, A.; Savard, J.; Chin, J.L.; et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: A study of escalating light doses. BJU Int. 2008, 102, 556–562. [CrossRef] [PubMed]
253. Azzouzi, A.R.; Barret, E.; Moore, C.M.; Villers, A.; Allen, C.; Scherz, A.; Muir, G.; de Wildt, M.; Barber, N.J.; Lebdai, S.; et al. Tookad® soluble vascular-targeted photodynamic (VTP) therapy: Determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int. 2013, 112, 766–774. [CrossRef] [PubMed]
254. Kawczyk-Krupka, A.; Wawrzyniec, K.; Musiol, S.K.; Potempa, M.; Bugaj, A.M.; Sieron, A. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-a review. Photodiagn. Photodyn. Ther. 2015, 12, 567–574. [CrossRef] [PubMed]
255. Stummer, W.; Pichlmeier, U.; Meinel, T.; Wiestler, O.D.; Zanella, F.; Reulen, H.J.; Group, A.L.-G.S. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase iii trial. Lancet Oncol. 2006, 7, 392–401. [CrossRef]
256. Stepp, H.; Beck, T.; Pongratz, T.; Meinel, T.; Kreth, F.W.; Tonn, J.; Stummer, W. ALA and malignant glioma: Fluorescence-guided resection and photodynamic treatment. J. Environ. Pathol. Toxicol. Oncol. 2007, 26, 157–164. [CrossRef] [PubMed]
257. Eljamel, M.S.; Goodman, C.; Moseley, H. ALA and photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: A single centre phase III randomised controlled trial. Lasers Med. Sci. 2008, 23, 361–367. [CrossRef] [PubMed]
258. Muller, P.J.; Wilson, B.C. Photodynamic therapy of brain tumors—A work in progress. Lasers Surg. Med. 2006, 38, 384–389. [CrossRef] [PubMed]
259. Kostron, H.; Fiegele, T.; Akatuna, E. Combination of foscan® mediated fluorescence guided resection and photodynamic treatment as new therapeutic concept for malignant brain tumors. Med. Laser Appl. 2006, 21, 285–290. [CrossRef]
260. Akimoto, J.; Haraoka, J.; Aizawa, K. Preliminary clinical report on safety and efficacy of photodynamic therapy using talaporfin sodium for malignant gliomas. Photodiagn. Photodyn. Ther. 2012, 9, 91–99. [CrossRef] [PubMed]
261. Muragaki, Y.; Akimoto, J.; Maruyama, T.; Iseki, H.; Ikuta, S.; Nitta, M.; Maebayashi, K.; Saito, T.; Okada, Y.; Kaneko, S.; et al. Phase II clinical study on intraoperative photodynamic therapy with talaporfin sodium and semiconductor laser in patients with malignant brain tumors. J. Neurosurg. 2013, 119, 845–852. [CrossRef] [PubMed]
262. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [CrossRef] [PubMed]
263. Nakamura, T.; Oinuma, T. Usefulness of photodynamic diagnosis and therapy using talaporfin sodium for an advanced-aged patient with inoperable gastric cancer (a secondary publication). Laser Ther. 2014, 23, 201–210. [CrossRef] [PubMed]
264. Van der Snoek, E.M.; den Hollander, J.C.; Aans, J.B.; Sterenborg, H.J.; van der Ende, M.E.; Robinson, D.J. Photodynamic therapy with systemic meta-tetrahydroxyphenylchlorin in the treatment of anal intraepithelial neoplasia, grade 3. Lasers Surg. Med. 2012, 44, 637–644. [CrossRef] [PubMed]
265. Welbourn, H.; Duthie, G.; Powell, J.; Moghissi, K. Can photodynamic therapy be the preferred treatment option for anal intraepithelial neoplasia? Initial results of a pilot study. Photodiagn. Photodyn. Ther. 2014, 11, 20–21. [CrossRef] [PubMed]
266. Boixadera, A.; Garcia-Arumi, J.; Martinez-Castillo, V.; Encinas, J.L.; Elizalde, J.; Blanco-Mateos, G.; Caminal, J.; Capeans, C.; Armada, F.; Navea, A.; et al. Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology 2009, 116, 100–105. [CrossRef] [PubMed]
267. Campbell, W.G.; Pejnovic, T.M. Treatment of amelanotic choroidal melanoma with photodynamic therapy. Retina 2012, 32, 1356–1362. [CrossRef] [PubMed]
268. Kaliki, S.; Shields, C.L.; Al-Dahmash, S.A.; Mashayekhi, A.; Shields, J.A. Photodynamic therapy for choroidal metastasis in 8 cases. Ophthalmology 2012, 119, 1218–1222. [CrossRef] [PubMed]
269. Blasi, M.A.; Tiberti, A.C.; Scupola, A.; Balestrazzi, A.; Colangelo, E.; Valente, P.; Balestrazzi, E. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: Five-year outcomes. Ophthalmology 2010, 117, 1630–1637. [CrossRef] [PubMed]
270. Fink, C.; Enk, A.; Gholam, P. Photodynamic therapy—Aspects of pain management. J. Dtsch Dermatol. Ges. 2015, 13, 15–22. [CrossRef] [PubMed]
271. Bugaj, A.M. Targeted photodynamic therapy—A promising strategy of tumor treatment. Photochem. Photobiol. Sci 2011, 10, 1097–1109. [CrossRef] [PubMed]
272. Sibani, S.A.; McCarron, P.A.; Woolfson, A.D.; Donnelly, R.F. Photosensitiser delivery for photodynamic therapy. Part 2: Systemic carrier platforms. Expert Opin. Drug Deliv. 2008, 5, 1241–1254. [CrossRef] [PubMed]
273. St Denis, T.G.; Hamblin, M.R. Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy. Bioanalysis 2013, 5, 1099–1114. [CrossRef] [PubMed]
274. Kascakova, S.; Hofland, L.J.; De Bruijn, H.S.; Ye, Y.; Achilefu, S.; van der Wansem, K.; van der Ploeg-van den Heuvel, A.; van Koetsveld, P.M.; Brugts, M.P.; van der Lelij, A.J.; et al. Somatostatin analogues for receptor targeted photodynamic therapy. PLoS ONE 2014, 9, e104448. [CrossRef] [PubMed]
275. Debele, T.A.; Peng, S.; Tsai, H.C. Drug carrier for photodynamic cancer therapy. Int. J. Mol. Sci. 2015, 16, 22094–22136. [CrossRef] [PubMed]
276. Huang, Y.Y.; Sharma, S.K.; Dai, T.; Chung, H.; Yaroslavsky, A.; Garcia-Diaz, M.; Chang, J.; Chiang, L.Y.; Hamblin, M.R. Can nanotechnology potentiate photodynamic therapy? Nanotechnol. Rev. 2012, 1, 111–146. [CrossRef] [PubMed]
277. Zhao, X.; Li, H.; Lee, R.J. Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv. 2008, 5, 309–319. [CrossRef] [PubMed]
278. Bahrami, B.; Mohammadnia-Afrouzi, M.; Bakhshaei, P.; Yazdani, Y.; Ghalamfarsa, G.; Yousefi, M.; Sadreddini, S.; Jadidi-Niaragh, F.; Hojjat-Farsangi, M. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumour Biol. 2015, 36, 5727–5742. [CrossRef] [PubMed]
279. Syu, W.J.; Yu, H.P.; Hsu, C.Y.; Rajan, Y.C.; Hsu, Y.H.; Chang, Y.C.; Hsieh, W.Y.; Wang, C.H.; Lai, P.S. Improved photodynamic cancer treatment by folate-conjugated polymeric micelles in a KB xenografted animal model. Small 2012, 8, 2060–2069. [CrossRef] [PubMed]
280. Vecchione, L.; Jacobs, B.; Normanno, N.; Ciardiello, F.; Tejpar, S. Egfr-targeted therapy. Exp. Cell Res. 2011, 317, 2765–2771. [CrossRef] [PubMed]
281. Master, A.M.; Qi, Y.; Oleinick, N.L.; Gupta, A.S. Egfr-mediated intracellular delivery of pc 4 nanoformulation for targeted photodynamic therapy of cancer: In vitro studies. Nanomedicine 2012, 8, 655–664. [CrossRef] [PubMed]
282. Master, A.; Malamas, A.; Solanki, R.; Clausen, D.M.; Eiseman, J.L.; Sen Gupta, A. A cell-targeted photodynamic nanomedicine strategy for head and neck cancers. Mol. Pharm. 2013, 10, 1988–1997. [CrossRef] [PubMed]
283. Gravier, J.; Schneider, R.; Frochot, C.; Bastogne, T.; Schmitt, F.; Didelon, J.; Guillemin, F.; Barberi-Heyob, M. Improvement of meta-tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. Synthesis and in vivo delivery studies. J. Med. Chem. 2008, 51, 3867–3877. [CrossRef] [PubMed]
284. You, H.; Yoon, H.E.; Jeong, P.H.; Ko, H.; Yoon, J.H.; Kim, Y.C. Pheophorbide-a conjugates with cancer-targeting moieties for targeted photodynamic cancer therapy. Bioorg. Med. Chem. 2015, 23, 1453–1462. [CrossRef] [PubMed]
285. Mew, D.; Wat, C.K.; Towers, G.H.; Levy, J.G. Photoimmunotherapy: Treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J. Immunol. 1983, 130, 1473–1477. [PubMed]
286. Van Dongen, G.A.; Visser, G.W.; Vrouenraets, M.B. Photosensitizer-antibody conjugates for detection and therapy of cancer. Adv. Drug Deliv. Rev. 2004, 56, 31–52. [CrossRef] [PubMed]
287. Kameyama, N.; Matsuda, S.; Itano, O.; Ito, A.; Konno, T.; Arai, T.; Ishihara, K.; Ueda, M.; Kitagawa, Y. Photodynamic therapy using an anti-egf receptor antibody complexed with verteporfin nanoparticles: A proof of concept study. Cancer Biother. Radiopharm. 2011, 26, 697–704. [CrossRef] [PubMed]
288. Mitsunaga, M.; Ogawa, M.; Kosaka, N.; Rosenblum, L.T.; Choyke, P.L.; Kobayashi, H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 2011, 17, 1685–1691. [CrossRef] [PubMed]
289. Nakajima, T.; Sano, K.; Choyke, P.L.; Kobayashi, H. Improving the efficacy of photoimmunotherapy (pit) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics 2013, 3, 357–365. [CrossRef] [PubMed]
290. Thurber, G.M.; Schmidt, M.M.; Wittrup, K.D. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 2008, 60, 1421–1434. [CrossRef] [PubMed]
291. Duska, L.R.; Hamblin, M.R.; Bamberg, M.P.; Hasan, T. Biodistribution of charged F(ab’)2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br. J. Cancer 1997, 75, 837–844. [CrossRef] [PubMed]
292. Kuimova, M.K.; Bhatti, M.; Deonarain, M.; Yahioglu, G.; Levitt, J.A.; Stamati, I.; Suhling, K.; Phillips, D. Fluorescence characterisation of multiply-loaded anti-HER2 single chain fv-photosensitizer conjugates suitable for photodynamic therapy. Photochem. Photobiol. Sci 2007, 6, 933–939. [CrossRef] [PubMed]
293. Staneloudi, C.; Smith, K.A.; Hudson, R.; Malatesti, N.; Savoie, H.; Boyle, R.W.; Greenman, J. Development and characterization of novel photosensitizer: Scfv conjugates for use in photodynamic therapy of cancer. Immunology 2007, 120, 512–517. [CrossRef] [PubMed]
294. Bhatti, M.; Yahioglu, G.; Milgrom, L.R.; Garcia-Maya, M.; Chester, K.A.; Deonarain, M.P. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int. J. Cancer 2008, 122, 1155–1163. [CrossRef] [PubMed]
295. Milgrom, L.R. Towards recombinant antibody-fragment targeted photodynamic therapy. Sci. Prog. 2008, 91, 241–263. [CrossRef] [PubMed]
296. Oliveira, S.; van Dongen, G.A.; Stigter-van Walsum, M.; Roovers, R.C.; Stam, J.C.; Mali, W.; van Diest, P.J.; van Bergen en Henegouwen, P.M. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol. Imaging 2012, 11, 33–46. [PubMed]
297. Heukers, R.; van Bergen en Henegouwen, P.M.; Oliveira, S. Nanobody-photosensitizer conjugates for targeted photodynamic therapy. Nanomedicine 2014, 10, 1441–1451. [CrossRef] [PubMed]
298. Van Driel, P.B.; Boonstra, M.C.; Slooter, M.D.; Heukers, R.; Stammes, M.A.; Snoeks, T.J.; de Bruijn, H.S.; van Diest, P.J.; Vahrmeijer, A.L.; van Bergen En Henegouwen, P.M.; et al. Egfr targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer. J. Control Release 2016, 229, 93–105. [CrossRef] [PubMed]
299. Wen, S.; Zhu, D.; Huang, P. Targeting cancer cell mitochondria as a therapeutic approach. Future Med. Chem. 2013, 5, 53–67. [CrossRef] [PubMed]
300. Chen, Y.; Sajjad, M.; Wang, Y.; Batt, C.; Nabi, H.A.; Pandey, R.K. TSPO 18 kDa (PBR) targeted photosensitizers for cancer imaging (PET) and PDT. ACS Med. Chem. Lett. 2011, 2, 136–141. [CrossRef] [PubMed]
301. Zhang, S.; Yang, L.; Ling, X.; Shao, P.; Wang, X.; Edwards, W.B.; Bai, M. Tumor mitochondria-targeted photodynamic therapy with a translocator protein (TSPO)-specific photosensitizer. Acta Biomater. 2015, 28, 160–170. [CrossRef] [PubMed]
302. Sandell, J.L.; Zhu, T.C. A review of in vivo optical properties of human tissues and its impact on PDT. J. Biophotonics 2011, 4, 773–787. [CrossRef] [PubMed]
303. Huang, Z.; Xu, H.; Meyers, A.D.; Musani, A.I.; Wang, L.; Tagg, R.; Barqawi, A.B.; Chen, Y.K. Photodynamic therapy for treatment of solid tumors—Potential and technical challenges. Technol. Cancer Res. Treat. 2008, 7, 309–320. [CrossRef] [PubMed]
304. Vogl, T.J.; Eichler, K.; Mack, M.G.; Zangos, S.; Herzog, C.; Thalhammer, A.; Engelmann, K. Interstitial photodynamic laser therapy in interventional oncology. Eur. Radiol. 2004, 14, 1063–1073. [CrossRef] [PubMed]
305. Huang, Z.; Haider, M.A.; Kraft, S.; Chen, Q.; Blanc, D.; Wilson, B.C.; Hetzel, F.W. Magnetic resonance imaging correlated with the histopathological effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland. Lasers Surg. Med. 2006, 38, 672–681. [CrossRef] [PubMed]
306. Beck, T.J.; Kreth, F.W.; Beyer, W.; Mehrkens, J.H.; Obermeier, A.; Stepp, H.; Stummer, W.; Baumgartner, R. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg. Med. 2007, 39, 386–393. [CrossRef] [PubMed]
307. Jerjes, W.; Upile, T.; Hamdoon, Z.; Abbas, S.; Akram, S.; Mosse, C.A.; Morley, S.; Hopper, C. Photodynamic therapy: The minimally invasive surgical intervention for advanced and/or recurrent tongue base carcinoma. Lasers Surg. Med. 2011, 43, 283–292. [CrossRef] [PubMed]
308. Jerjes, W.; Upile, T.; Alexander Mosse, C.; Hamdoon, Z.; Morcos, M.; Morley, S.; Hopper, C. Prospective evaluation of 110 patients following ultrasound-guided photodynamic therapy for deep seated pathologies. Photodiagn. Photodyn. Ther. 2011, 8, 297–306. [CrossRef] [PubMed]
309. Sajisevi, M.; Rigual, N.R.; Bellnier, D.A.; Seshadri, M. Image-guided interstitial photodynamic therapy for squamous cell carcinomas: Preclinical investigation. J. Oral Maxillofac. Surg. Med. Pathol. 2015, 27, 159–165. [CrossRef] [PubMed]
310. Chang, C.; Wang, K.K.; Zhu, T.C. A fast heterogeneous algorithm for light fluence rate for prostate photodynamic therapy. Proc. SPIE Int. Soc. Opt. Eng. 2010. [CrossRef]
311. Gibson, A.P.; Hebden, J.C.; Arridge, S.R. Recent advances in diffuse optical imaging. Phys. Med. Biol. 2005, 50, R1–R43. [CrossRef] [PubMed]
312. Liang, X.; Wang, K.K.; Zhu, T.C. Characterization of tissue optical properties for prostate PDT using interstitial diffuse optical tomography. Proc. SPIE Int. Soc. Opt. Eng. 2012. [CrossRef]
313. Finlay, J.C.; Zhu, T.C.; Dimofte, A.; Stripp, D.; Malkowicz, S.B.; Whittington, R.; Miles, J.; Glatstein, E.; Hahn, S.M. In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy. Proc. SPIE Int. Soc. Opt. Eng. 2014, 5315, 132–142. [PubMed]
314. Swartling, J.; Axelsson, J.; Ahlgren, G.; Kalkner, K.M.; Nilsson, S.; Svanberg, S.; Svanberg, K.; Andersson-Engels, S. System for interstitial photodynamic therapy with online dosimetry: First clinical experiences of prostate cancer. J. Biomed. Opt. 2010. [CrossRef] [PubMed]
315. Sharikova, A.V.; Finlay, J.C.; Dimofte, A.; Zhu, T.C. A robotic multi-channel platform for interstitial photodynamic therapy. Proc. SPIE Int. Soc. Opt. Eng. 2013. [CrossRef]
316. Hockel, M.; Vaupel, P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 2001, 93, 266–276. [CrossRef] [PubMed]
317. Bozzini, G.; Colin, P.; Betrouni, N.; Maurage, C.A.; Leroy, X.; Simonin, S.; Martin-Schmitt, C.; Villers, A.; Mordon, S. Efficiency of 5-ALA mediated photodynamic therapy on hypoxic prostate cancer: A preclinical study on the dunning R3327-AT2 rat tumor model. Photodiagn. Photodyn. Ther. 2013, 10, 296–303. [CrossRef] [PubMed]
318. Weston, M.A.; Patterson, M.S. Validation and application of a model of oxygen consumption and diffusion during photodynamic therapy in vitro. Photochem. Photobiol. 2014, 90, 1359–1367. [CrossRef] [PubMed]
319. Albert, I.; Hefti, M.; Luginbuehl, V. Physiological oxygen concentration alters glioma cell malignancy and responsiveness to photodynamic therapy in vitro. Neurol. Res. 2014, 36, 1001–1010. [CrossRef] [PubMed]
320. Kishimoto, S.; Bernardo, M.; Saito, K.; Koyasu, S.; Mitchell, J.B.; Choyke, P.L.; Krishna, M.C. Evaluation of oxygen dependence on in vitro and in vivo cytotoxicity of photoimmunotherapy using IR-700-antibody conjugates. Free Radic. Biol. Med. 2015, 85, 24–32. [CrossRef] [PubMed]
321. Li, W.; Huang, D.; Zhang, Y.; Liu, Y.; Gu, Y.; Qian, Z. Real-time monitoring of singlet oxygen and oxygen partial pressure during the deep photodynamic therapy in vitro. Ann. Biomed. Eng. 2016, 44, 2737–2745. [CrossRef] [PubMed]
322. Pogue, B.W.; Hasan, T. A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiat. Res. 1997, 147, 551–559. [CrossRef] [PubMed]
323. Babilas, P.; Schacht, V.; Liebsch, G.; Wolfbeis, O.S.; Landthaler, M.; Szeimies, R.M.; Abels, C. Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo. Br. J. Cancer 2003, 88, 1462–1469. [CrossRef] [PubMed]
324. Pogue, B.W.; Sheng, C.; Benevides, J.; Forcione, D.; Puricelli, B.; Nishioka, N.; Hasan, T. Protoporphyrin ix fluorescence photobleaching increases with the use of fractionated irradiation in the esophagus. J. Biomed. Opt. 2008. [CrossRef] [PubMed]
325. Middelburg, T.A.; de Bruijn, H.S.; van der Ploeg-van den Heuvel, A.; Neumann, H.A.; Robinson, D.J. The effect of light fractionation with a 2-h dark interval on the efficacy of topical hexyl-aminolevulinate photodynamic therapy in normal mouse skin. Photodiagn. Photodyn. Ther. 2013, 10, 703–709. [CrossRef] [PubMed]
326. Turan, I.S.; Yildiz, D.; Turksoy, A.; Gunaydin, G.; Akkaya, E.U. A bifunctional photosensitizer for enhanced fractional photodynamic therapy: Singlet oxygen generation in the presence and absence of light. Angew. Chem. Int. Ed. 2016, 55, 2875–2878. [CrossRef] [PubMed]
327. Liu, Y.; Liu, Y.; Bu, W.; Cheng, C.; Zuo, C.; Xiao, Q.; Sun, Y.; Ni, D.; Zhang, C.; Liu, J.; et al. Hypoxia induced by upconversion-based photodynamic therapy: Towards highly effective synergistic bioreductive therapy in tumors. Angew. Chem. Int. Ed. 2015, 54, 8105–8109. [CrossRef] [PubMed]
328. Tomaselli, F.; Maier, A.; Sankin, O.; Anegg, U.; Stranzl, U.; Pinter, H.; Kapp, K.; Smolle-Juttner, F.M. Acute effects of combined photodynamic therapy and hyperbaric oxygenation in lung cancer—A clinical pilot study. Lasers Surg. Med. 2001, 28, 399–403. [CrossRef] [PubMed]
329. Moen, I.; Stuhr, L.E. Hyperbaric oxygen therapy and cancer—A review. Target. Oncol. 2012, 7, 233–242. [CrossRef] [PubMed]
330. Evans, C.L.; Abu-Yousif, A.O.; Park, Y.J.; Klein, O.J.; Celli, J.P.; Rizvi, I.; Zheng, X.; Hasan, T. Killing hypoxic cell populations in a 3d tumor model with etnbs-PDT. PLoS ONE 2011, 6, e23434. [CrossRef] [PubMed]
331. Klein, O.J.; Bhayana, B.; Park, Y.J.; Evans, C.L. In vitro optimization of EtNBS-PDT against hypoxic tumor environments with a tiered, high-content, 3D model optical screening platform. Mol. Pharm. 2012, 9, 3171–3182. [CrossRef] [PubMed]
332. Wilson, B.C.; Patterson, M.S.; Lilge, L. Implicit and explicit dosimetry in photodynamic therapy: A new paradigm. Lasers Med. Sci. 1997, 12, 182–199. [CrossRef] [PubMed]
333. Woodburn, K.; Chang, C.K.; Lee, S.; Henderson, B.; Kessel, D. Biodistribution and PDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle. Photochem. Photobiol. 1994, 60, 154–159. [CrossRef] [PubMed]
334. Aveline, B.; Hasan, T.; Redmond, R.W. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem. Photobiol. 1994, 59, 328–335. [CrossRef] [PubMed]
335. Wang, K.K.; Mitra, S.; Foster, T.H. A comprehensive mathematical model of microscopic dose deposition in photodynamic therapy. Med. Phys. 2007, 34, 282–293. [CrossRef] [PubMed]
336. Pogue, B.W.; Paulsen, K.D.; O’Hara, J.A.; Wilmot, C.M.; Swartz, H.M. Estimation of oxygen distribution in RIF-1 tumors by diffusion model-based interpretation of pimonidazole hypoxia and eppendorf measurements. Radiat. Res. 2001, 155, 15–25. [CrossRef]
337. Wang, H.W.; Putt, M.E.; Emanuele, M.J.; Shin, D.B.; Glatstein, E.; Yodh, A.G.; Busch, T.M. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome. Cancer Res. 2004, 64, 7553–7561. [CrossRef] [PubMed]
338. Kruijt, B.; de Bruijn, H.S.; van der Ploeg-van den Heuvel, A.; Sterenborg, H.J.; Robinson, D.J. Laser speckle imaging of dynamic changes in flow during photodynamic therapy. Lasers Med. Sci. 2006, 21, 208–212. [CrossRef] [PubMed]
339. Yu, G.; Durduran, T.; Zhou, C.; Zhu, T.C.; Finlay, J.C.; Busch, T.M.; Malkowicz, S.B.; Hahn, S.M.; Yodh, A.G. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light. Photochem. Photobiol. 2006, 82, 1279–1284. [CrossRef] [PubMed]
340. Nijssen, A.; Koljenovic, S.; Bakker Schut, T.C.; Caspers, P.J.; Puppels, G.J. Towards oncological application of raman spectroscopy. J. Biophotonics 2009, 2, 29–36. [CrossRef] [PubMed]
341. Khurana, M.; Moriyama, E.H.; Mariampillai, A.; Wilson, B.C. Intravital high-resolution optical imaging of individual vessel response to photodynamic treatment. J. Biomed. Opt. 2008. [CrossRef] [PubMed]
342. Van Leeuwen-van Zaane, F.; Gamm, U.A.; van Driel, P.B.A.A.; Snoeks, T.J.; de Bruijn, H.S.; van der Ploeg-van den Heuvel, A.; Sterenborg, H.J.C.M.; Löwik, C.W.; Amelink, A.; Robinson, D.J. Intrinsic photosensitizer fluorescence measured using multi-diameter single-fiber spectroscopy in vivo. J. Biomed. Opt. 2014. [CrossRef] [PubMed]
343. Sibai, M.; Veilleux, I.; Elliott, J.T.; Leblond, F.; Wilson, B.C. Quantitative spatial frequency fluorescence imaging in the sub-diffusive domain for image-guided glioma resection. Biomed. Opt. Express 2015, 6, 4923–4933. [CrossRef] [PubMed]
344. Middelburg, T.A.; Hoy, C.L.; Neumann, H.A.; Amelink, A.; Robinson, D.J. Correction for tissue optical properties enables quantitative skin fluorescence measurements using multi-diameter single fiber reflectance spectroscopy. J. Dermatol. Sci. 2015, 79, 64–73. [CrossRef] [PubMed]
345. Gallagher-Colombo, S.M.; Quon, H.; Malloy, K.M.; Ahn, P.H.; Cengel, K.A.; Simone, C.B., II; Chalian, A.A.; O’Malley, B.W.; Weinstein, G.S.; Zhu, T.C.; et al. Measuring the physiologic properties of oral lesions receiving fractionated photodynamic therapy. Photochem. Photobiol. 2015, 91, 1210–1218. [CrossRef] [PubMed]
346. De Souza, A.L.; Marra, K.; Gunn, J.; Samkoe, K.S.; Kanick, S.C.; Davis, S.C.; Chapman, M.S.; Maytin, E.V.; Hasan, T.; Pogue, B.W. Comparing desferrioxamine and light fractionation enhancement of ALA-PPIX photodynamic therapy in skin cancer. Br. J. Cancer 2016, 115, 805–813. [CrossRef] [PubMed]
347. Zaak, D.; Karl, A.; Knuchel, R.; Stepp, H.; Hartmann, A.; Reich, O.; Bachmann, A.; Siebels, M.; Popken, G.; Stief, C. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int. 2005, 96, 217–222. [CrossRef] [PubMed]
348. Lovell, J.F.; Liu, T.W.; Chen, J.; Zheng, G. Activatable photosensitizers for imaging and therapy. Chem. Rev. 2010, 110, 2839–2857. [CrossRef] [PubMed]
349. Rai, P.; Mallidi, S.; Zheng, X.; Rahmanzadeh, R.; Mir, Y.; Elrington, S.; Khurshid, A.; Hasan, T. Development and applications of photo-triggered theranostic agents. Adv. Drug Deliv. Rev. 2010, 62, 1094–1124. [CrossRef] [PubMed]
350. Kim, H.; Chung, K.; Lee, S.; Kim, D.H.; Lee, H. Near-infrared light-responsive nanomaterials for cancer theranostics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016, 8, 23–45. [CrossRef] [PubMed]
351. Gupta, A.; Wang, S.; Marko, A.; Joshi, P.; Ethirajan, M.; Chen, Y.; Yao, R.; Sajjad, M.; Kopelman, R.; Pandey, R.K. Polyacrylamide-based biocompatible nanoplatform enhances the tumor uptake, PET/fluorescence imaging and anticancer activity of a chlorophyll analog. Theranostics 2014, 4, 614–628. [CrossRef] [PubMed]
352. Entract, G.M.; Bryden, F.; Domarkas, J.; Savoie, H.; Allott, L.; Archibald, S.J.; Cawthorne, C.; Boyle, R.W. Development of PDT/PET theranostics: Synthesis and biological evaluation of an (18)F-radiolabeled water-soluble porphyrin. Mol. Pharm. 2015, 12, 4414–4423. [CrossRef] [PubMed]
353. Muhanna, N.; Cui, L.; Chan, H.; Burgess, L.; Jin, C.S.; MacDonald, T.D.; Huynh, E.; Wang, F.; Chen, J.; Irish, J.C.; et al. Multimodal image-guided surgical and photodynamic interventions in head and neck cancer: From primary tumor to metastatic drainage. Clin. Cancer Res. 2016, 22, 961–970. [CrossRef] [PubMed]
354. Lu, S.; Tu, D.; Hu, P.; Xu, J.; Li, R.; Wang, M.; Chen, Z.; Huang, M.; Chen, X. Multifunctional nano-bioprobes based on rattle-structured upconverting luminescent nanoparticles. Angew. Chem. Int. Ed. 2015, 54, 7915–7919. [CrossRef] [PubMed]
355. Li, Y.; Lin, T.Y.; Luo, Y.; Liu, Q.; Xiao, W.; Guo, W.; Lac, D.; Zhang, H.; Feng, C.; Wachsmann-Hogiu, S.; et al. A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat. Commun. 2014. [CrossRef] [PubMed]
356. Song, X.; Liang, C.; Gong, H.; Chen, Q.; Wang, C.; Liu, Z. Photosensitizer-conjugated albumin-polypyrrole nanoparticles for imaging-guided in vivo photodynamic/photothermal therapy. Small 2015, 11, 3932–3941. [CrossRef] [PubMed]
357. Schmitt, J.; Heitz, V.; Sour, A.; Bolze, F.; Kessler, P.; Flamigni, L.; Ventura, B.; Bonnet, C.S.; Toth, E. A theranostic agent combining a two-photon-absorbing photosensitizer for photodynamic therapy and a gadolinium(iii) complex for mri detection. Chemistry 2016, 22, 2775–2786. [CrossRef] [PubMed]
358. Guo, M.; Mao, H.; Li, Y.; Zhu, A.; He, H.; Yang, H.; Wang, Y.; Tian, X.; Ge, C.; Peng, Q.; et al. Dual imaging-guided photothermal/photodynamic therapy using micelles. Biomaterials 2014, 35, 4656–4666. [CrossRef] [PubMed]
359. Taratula, O.; Patel, M.; Schumann, C.; Naleway, M.A.; Pang, A.J.; He, H.; Taratula, O. Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy. Int. J. Nanomed. 2015, 10, 2347–2362. [CrossRef] [PubMed]
360. Lv, R.; Yang, P.; He, F.; Gai, S.; Li, C.; Dai, Y.; Yang, G.; Lin, J. A yolk-like multifunctional platform for multimodal imaging and synergistic therapy triggered by a single near-infrared light. ACS Nano 2015, 9, 1630–1647. [CrossRef] [PubMed]
361. Master, A.; Livingston, M.; Sen Gupta, A. Photodynamic nanomedicine in the treatment of solid tumors: Perspectives and challenges. J. Control Release 2013, 168, 88–102. [CrossRef] [PubMed]
362. Gollnick, S.O.; Brackett, C.M. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol. Res. 2010, 46, 216–226. [CrossRef] [PubMed]
363. Mroz, P.; Szokalska, A.; Wu, M.X.; Hamblin, M.R. Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response. PLoS ONE 2010, 5, e15194. [CrossRef] [PubMed]
364. Thong, P.S.; Ong, K.W.; Goh, N.S.; Kho, K.W.; Manivasager, V.; Bhuvaneswari, R.; Olivo, M.; Soo, K.C. Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol. 2007, 8, 950–952. [CrossRef]
365. Abdel-Hady, E.S.; Martin-Hirsch, P.; Duggan-Keen, M.; Stern, P.L.; Moore, J.V.; Corbitt, G.; Kitchener, H.C.; Hampson, I.N. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001, 61, 192–196. [PubMed]
366. Anzengruber, F.; Avci, P.; de Freitas, L.F.; Hamblin, M.R. T-cell mediated anti-tumor immunity after photodynamic therapy: Why does it not always work and how can we improve it? Photochem. Photobiol. Sci. 2015, 14, 1492–1509. [CrossRef] [PubMed]
367. Mroz, P.; Hashmi, J.T.; Huang, Y.Y.; Lange, N.; Hamblin, M.R. Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev. Clin. Immunol. 2011, 7, 75–91. [CrossRef] [PubMed]
368. St Denis, T.G.; Aziz, K.; Waheed, A.A.; Huang, Y.Y.; Sharma, S.K.; Mroz, P.; Hamblin, M.R. Combination approaches to potentiate immune response after photodynamic therapy for cancer. Photochem. Photobiol. Sci. 2011, 10, 792–801. [CrossRef] [PubMed]
369. Xia, Y.; Gupta, G.K.; Castano, A.P.; Mroz, P.; Avci, P.; Hamblin, M.R. Cpg oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. J. Biophotonics 2014, 7, 897–905. [CrossRef] [PubMed]
370. Marrache, S.; Choi, J.H.; Tundup, S.; Zaver, D.; Harn, D.A.; Dhar, S. Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer. Integr. Biol. 2013, 5, 215–223. [CrossRef] [PubMed]
371. Korbelik, M.; Banath, J.; Saw, K.M.; Zhang, W.; Ciplys, E. Calreticulin as cancer treatment adjuvant: Combination with photodynamic therapy and photodynamic therapy-generated vaccines. Front. Oncol. 2015. [CrossRef] [PubMed]
372. Shams, M.; Owczarczak, B.; Manderscheid-Kern, P.; Bellnier, D.A.; Gollnick, S.O. Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease. Cancer Immunol. Immunother. 2015, 64, 287–297. [CrossRef] [PubMed]
373. Castano, A.P.; Mroz, P.; Wu, M.X.; Hamblin, M.R. Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc. Natl. Acad. Sci. USA 2008, 105, 5495–5500. [CrossRef] [PubMed]
374. Reginato, E.; Mroz, P.; Chung, H.; Kawakubo, M.; Wolf, P.; Hamblin, M.R. Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. Br. J. Cancer 2013, 109, 2167–2174. [CrossRef] [PubMed]
375. Igney, F.H.; Krammer, P.H. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 2002, 71, 907–920. [PubMed]
376. Mroz, P.; Vatansever, F.; Muchowicz, A.; Hamblin, M.R. Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. Cancer Res. 2013, 73, 6462–6470. [CrossRef] [PubMed]
377. Wachowska, M.; Gabrysiak, M.; Muchowicz, A.; Bednarek, W.; Barankiewicz, J.; Rygiel, T.; Boon, L.; Mroz, P.; Hamblin, M.R.; Golab, J. 5-Aza-2’-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Eur. J. Cancer 2014, 50, 1370–1381. [CrossRef] [PubMed]
378. Korbelik, M. Cancer vaccines generated by photodynamic therapy. Photochem. Photobiol. Sci. 2011, 10, 664–669. [CrossRef] [PubMed]
379. Zheng, Y.; Yin, G.; Le, V.; Zhang, A.; Chen, S.; Liang, X.; Liu, J. Photodynamic-therapy activates immune response by disrupting immunity homeostasis of tumor cells, which generates vaccine for cancer therapy. Int. J. Biol. Sci. 2016, 12, 120–132. [CrossRef] [PubMed]
380. Jung, N.C.; Kim, H.J.; Kang, M.S.; Lee, J.H.; Song, J.Y.; Seo, H.G.; Bae, Y.S.; Lim, D.S. Photodynamic therapy-mediated DC immunotherapy is highly effective for the inhibition of established solid tumors. Cancer Lett. 2012, 324, 58–65. [CrossRef] [PubMed]
381. Ji, J.; Fan, Z.; Zhou, F.; Wang, X.; Shi, L.; Zhang, H.; Wang, P.; Yang, D.; Zhang, L.; Chen, W.R.; et al. Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncotarget 2015, 6, 17135–17146. [CrossRef]
382. Marrache, S.; Tundup, S.; Harn, D.A.; Dhar, S. Ex vivo generation of functional immune cells by mitochondria-targeted photosensitization of cancer cells. Methods Mol. Biol. 2015, 1265, 113–122. [PubMed]
383. Shixiang, Y.; Xi, S.; Junliang, L.; Shanyi, Z.; Xingke, X.; Meiguang, Z.; Kai, W.; Fangcheng, L. Antitumor efficacy of a photodynamic therapy-generated dendritic cell glioma vaccine. Med. Oncol. 2011, 28 (Suppl. S1), S453–461. [CrossRef] [PubMed]
384. Korbelik, M.; Banath, J.; Saw, K.M. Immunoregulatory cell depletion improves the efficacy of photodynamic therapy-generated cancer vaccines. Int. J. Mol. Sci. 2015, 16, 27005–27014. [CrossRef] [PubMed]
385. Moghissi, K. PDT: The plight. Photodiagn. Photodyn. Ther. 2007. [CrossRef] [PubMed]
386. Moghissi, K.; Dixon, K.; Gibbins, S. A surgical view of photodynamic therapy in oncology: A review. Surg. J. 2015, 1, e1–e15.